```
=> d his

     (FILE 'HOME' ENTERED AT 13:08:23 ON 19 APR 1999)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 13:08:29 ON 19 APR 1999
               E MICHALSKI T/AU
L1          37 S E3,E4,E6-E10
               E TWYMAN D/AU
L2           8 S E4
               E MARK D/AU
L3          71 S E3,E4,E9,E10
               E NESTEC/PA,CS
L4         565 S E3,E4
L5         672 S L1-L4
L6          15 S ENTERAL? AND L5
L7          35 S WHEY AND L5
L8          11 S L7 AND ?LIPID?
L9           6 S L7 AND FATTY
L10          5 S L7 AND TRIGLYCERIDE
L11          6 S L7 AND GLYCERIDE
L12          7 S L7 AND FAT
L13         12 S L8-L12
L14          8 S L13 AND CARBOHYDRATE#/SC,SX,CW,BI,AB
L15          2 S L13 AND ?SACCHARID?
L16          0 S L13 AND DEXTROSE
L17          0 S L13 AND GLUCOSE
L18          9 S L14,L15
L19          8 S L7 AND (LONG OR MEDIUM)
L20          6 S L19 AND CARBOHYDRATE#/SC,SX,CW,BI,AB
L21          1 S L19 AND ?SACCHARID?
L22          1 S L19 AND (DEXTROSE OR SUCROSE)
L23         10 S L18-L22
L24          1 S L23 NOT L18
L25          9 S L18 NOT L24

     FILE 'REGISTRY' ENTERED AT 13:39:30 ON 19 APR 1999
L26         14 S (ALANINE OR ARGININE OR ASPARAGINE OR ASPARTIC ACID OR CYSTEI
L27         13 S (GLYCINE OR HISTIDINE OR ISOLEUCINE OR LEUCINE OR LYSINE OR M
L28         12 S (PROLINE OR SERINE OR THREONINE OR TRYPTOPHAN OR TYROSINE OR
L29          8 S 302-72-7 OR 7200-25-1 OR 3130-87-8 OR 617-45-8 OR 3374-22-9 O
L30         11 S 443-79-8 OR 328-39-2 OR 70-54-2 OR 59-51-8 OR 150-30-1 OR 609
L31         10 S 338-69-2 OR 157-06-2 OR 2058-58-4 OR 1783-96-6 OR 921-01-7 OR
L32          9 S 923-27-3 OR 348-67-4 OR 673-06-3 OR 344-25-2 OR 312-84-5 OR 6
L33          9 S 56-41-7 OR 74-79-3 OR 70-47-3 OR 56-84-8 OR 52-90-4 OR 56-86-
L34         11 S 73-32-5 OR 61-90-5 OR 56-87-1 OR 63-68-3 OR 63-91-2 OR 147-85
L35         58 S L26-L34
L36          2 S DEXTROSE/CN OR GLUCOSE/CN
L37          1 S 7440-66-6
L38          1 S 50-81-7
L39          1 S 7782-49-2
L40          1 S 107-35-7
L41          1 S 541-15-1
               E C7H15NO3/MF
L42          4 S E3 AND  CARNITINE
L43          3 S L42 NOT 14C

     FILE 'HCAPLUS' ENTERED AT 13:52:24 ON 19 APR 1999
```

```
L44      198477 S L35
L45       10698 S WHEY
L46     1334447 S PROTEIN OR POLYPEPTIDE OR PEPTIDE OR NITROGEN SOURCE
L47     1467584 S L44-L46
L48      124081 S L47 AND (CARBOHYDRATE#/SC,SX,CW,BI,AB OR ?SACCHARIDE? OR L36
L49       25362 S L48 AND (TRIGLYCERIDE OR FATTY OR GLYCERIDE OR ?LIPID? OR FAT

     FILE 'REGISTRY' ENTERED AT 13:56:26 ON 19 APR 1999
               E .BETA.-CAROTENE/CN

     FILE 'HCAPLUS' ENTERED AT 13:56:49 ON 19 APR 1999
L50        3998 S L48 AND (GLYCERIDIC OR OIL)

     FILE 'REGISTRY' ENTERED AT 13:59:09 ON 19 APR 1999

     FILE 'HCAPLUS' ENTERED AT 13:59:18 ON 19 APR 1999
L51       26447 S L49,L50
L52         323 S L51 AND (L35 OR ZINC OR ZN) AND (L38 OR VITAMIN? C OR ASCORBI
L53          12 S L52 AND (L39 OR SELENIUM OR SE) AND (L40 OR TAURINE) AND (L43

     FILE 'REGISTRY' ENTERED AT 14:01:01 ON 19 APR 1999
L54           1 S .BETA.-CAROTENE/CN

     FILE 'HCAPLUS' ENTERED AT 14:01:10 ON 19 APR 1999
L55           8 S L53 AND (L54 OR CAROTENE)
L56          19 S L5 AND L51
L57          15 S L25,L55
L58           9 S L56 NOT L57
L59           3 S L58 AND ENTERAL?
L60           3 S L58 AND 1/SC,SX
L61          18 S L57,L59,L60
L62         129 S L51 AND ENTERAL?
L63          30 S L62 AND 63/SC
L64          22 S L63 NOT L61
L65          20 S L64 AND P/DT
L66           2 S L64 NOT L65
L67           1 S L66 NOT OSMOLALITY/TI
L68          39 S L61,L65,L67
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 14:09:22 ON 19 APR 1999
L69          26 S E1-E26

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:09:57 ON 19 APR 1999
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1999 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 19 Apr 1999  VOL 130 ISS 17
FILE LAST UPDATED: 19 Apr 1999  (19990419/ED)
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGistRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d bib abs hitrn tot l68

L68 ANSWER 1 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1998:804140 HCAPLUS
DN 130:43376
TI Composition and method for providing glutamine
IN Ballevre, Olivier; Anantharaman, Krishna; Boza, Julio; Garcia-Rodenas, Clara L.
PA Societe Des Produits Nestle S.A., Switz.
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9854986	A1	19981210	WO 98-EP2990	19980512
W: AU, BR, CA, CN, ID, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5849335	A	19981215	US 97-869866	19970602
PRAI US 97-869866		19970602		

AB A nutritional compn. for providing glutamine to a human or animal. The **protein** source of the compn. includes carob **protein** which is rich in glutamine. A source of methionine may also be included. The compn. may be used in the treatment of stressed patients, for example those patients who are critically ill, suffering from sepsis, injury, burns, or inflammation, or who are recovering from surgery. Further, the compn. may be used to raise plasma glutamine levels, for example in athletes after intense exercise.
IT **52-90-4**, L-Cysteine, biological studies **56-85-9**, L-Glutamine, biological studies **63-68-3**, L-Methionine, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compn. and method for providing glutamine, esp. for stressed patients)

L68 ANSWER 2 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1998:804139 HCAPLUS
DN 130:43375
TI Product and method for providing glutamine
IN Trimbo, Susan L.; Melin, Christian; Boza, Julio
PA Societe Des Produits Nestle S.A., Switz.
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9854985	A1	19981210	WO 98-EP2798	19980506

W: AU, BR, CA, CN, ID, JP, MX
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRAI US 97-48250 19970602
AB This invention provides a nutritional product and method for delivering glutamine to a patient. The nutritional product has a **protein** source which includes a cereal **protein**. The cereal **protein** may be oat **protein**, sorghum **protein**, or millet **protein**. The nutritional product also includes a **carbohydrate** source and a **lipid** source.
IT **56-85-9**, L-Glutamine, biological studies **56-87-1**, L-Lysine, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(product and method for providing glutamine)

L68 ANSWER 3 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1998:668007 HCAPLUS
DN 129:306506
TI **Enteral** formulation low in **fat** and containing **protein** hydrolyzates
IN Forse, R. Amour; Bell, Stacey J.; Burke, Peter
PA Beth Israel Deaconess Medical Center, Inc., USA
SO U.S., 5 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5821217	A	19981013	US 95-549062	19951027

AB An improved **enteral** formulation that is low in **fat** and contains **protein** hydrolyzates has been developed. The osmolality of the formulation is controlled to be below 500 mOs/kg H2O, preferably about 300 mOs/kg H2O. In a preferred embodiment, the formulation contains corn starch to control blood **glucose** levels. This formulation is particularly useful for treatment of critically ill patients and in minimizing a risk of pulmonary aspiration and/or gastrointestinal dysfunction in such patients. Basic ingredients of the **enteral** formulation included safflower **oils** 3, casein hydrolyzates (or **whey protein** hydrolyzates) 70, and **carbohydrates** (from sugars, corn starch, **oligosaccharides**, fructose, corn syrup, or sucrose) 180 g/L.

L68 ANSWER 4 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1998:202666 HCAPLUS
DN 128:275093
TI **Enteral** formulation designed for optimized wound healing
IN Barbul, Adrian; Bebenek, Lisa Stewart; **Mark, David A.**; Trimbo, Susan; **Twyman, Diana**; Lin, Paul
PA **Nestec** Ltd., Switz.
SO U.S., 13 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5733884	A	19980331	US 95-554475	19951107

AB An **enteral** nutritional formulation that meets the nutrient requirements of patients with wounds is provided. The present invention meets the unique nutrient needs of the acute or chronic patient that are generated due to tissue repair and healing requirements of wounds. To this end, in an embodiment, the present invention provides a method for providing nutritional support to a patient with an acute or chronic wound comprising the step of administering a therapeutically effective amt. of compn. comprising a **protein** source including an arginine source and a proline source in the ratio by wt. of approx. 1:0.5 to about 4:1. The compn. may also include a **carbohydrate** source, a **lipid** source including an appropriate n6:n3 ratio, and at least the U.S. RDA for vitamins and minerals provided in an amt. of formula supplying 1000 kcal, with vitamin A, beta-carotene, vitamin C, vitamin E, thiamine, pyridoxine, biotin and zinc being supplied in amts. above the U.S. RDAs. A liq. ready-to-use compn. contained **protein** 15.625, **carbohydrate** 28.175, **fat** 8.65 g, vitamin A 1000, vitamin D 100, vitamin E 15 IU, thiamin 0.75, pyridoxine 1.0 beta-carotene 0.5, zinc 6, copper 0.5, magnesium 100, 25, sodium 219, potassium 375, chloride 325 mg, selenium 25, and biotin 100 .mu.g. The efficacy of the compn. in the treatment of wounds induced in rats is shown.

IT **74-79-3**, Arginine, biological studies **147-85-3**, Proline, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**enteral** formulation designed for optimized wound healing)

L68 ANSWER 5 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1998:175314 HCAPLUS
DN 128:208942
TI **Enteral** formulation designed for optimized nutrient absorption and wound healing
IN Gray, Debora; Schmelkin, Nancy S.; Alexander, John; **Mark, David A.**; **Twyman, Diana**
PA **Nestec** Ltd., Switz.
SO U.S., 5 pp. Cont. of U. S. Ser. No. 172,857, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5723446	A	19980303	US 96-680703	19960717
PRAI	US 93-172857		19931223		

AB An **enteral** nutritional formulation that meets the nutrient requirements of intensive care patients who may have compromised absorption capacity is provided. The formulation meets the unique nutrient needs of the patient that are generated due to tissue repair and healing requirements. To this end, in an embodiment the present invention provides a method for treating and/or providing nutritional support to intensive care patients comprising the steps of administering a therapeutically effective amt. of a compn. comprising: a **protein** source; a **carbohydrate** source; and a **lipid** source including a source of medium chain **triglycerides**, a source of omega-3 **fatty** acids, and a source of omega-6 **fatty** acids. A liq., ready-to-use **enteral** product contained **protein** at 25% of total calories (87% from partially hydrolyzed casein and 13% from the free amino acid arginine), **carbohydrates** at 35-40% of calories, **lipids** at 38-42% of calories [preferably a blend of medium chain **triglycerides** (50%), fish **oil**

(25%), soya **oil** and soya lecithin (25%) total of both soya], vitamin and mineral content would meet preferably daily requirements in 1500 cal.

IT **52-90-4**, Cystein, biological studies **74-79-3**, Arginine, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**enteral** formulation designed for optimized nutrient absorption and wound healing)

L68 ANSWER 6 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1998:115397 HCAPLUS
DN 128:158945
TI Enteral formulation designed for optimized nutrient absorption and wound healing
IN Gray, Debora; Schmelkin, Nancy S.; Alexander, John; **Mark, David A.**; **Twyman, Diana**
PA **Nestec** Ltd., Switz.
SO U.S., 6 pp. Cont.-in-part of U.S. Ser. No. 172,587, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5714472	A	19980203	US 95-530877	19950920
	EP 764405	A2	19970326	EP 96-202637	19960920
	EP 764405	A3	19980429		

R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE

PRAI US 93-172587 19931223
US 95-530877 19950920

AB The present invention provides an enteral nutritional formulation that meets the nutrient requirements of intensive care patients who may have compromised absorption capacity. The present invention meets the unique nutrient needs of the patient that are generated due to tissue repair and healing requirements. A method for providing nutritional support to intensive care patients comprises the steps of administering a therapeutically effective amt. of a compn. contg. a protein source, a **carbohydrate** source, and a **lipid** source including a source of medium-chain **triglycerides**, a source of .omega.-3 **fatty** acids, and a source of .omega.-6 **fatty** acids. A liq., ready-to-use enteral product comprised (1) protein sources at 25% of total calories contg. partially hydrolyzed casein 50 %, partially hydrolyzed **whey** protein 34 %, arginine 12 %, and proline 4 %, (2) **carbohydrates** at 35-40 % of total calories, and (3) **lipids** at 38-42% of total calories, preferably a blend of medium-chain **triglycerides** 50 %, fish oil 25 %, and soy oil/soy lecithins 25%.

L68 ANSWER 7 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1998:98319 HCAPLUS
DN 128:158932
TI Amino acid compositions and use thereof in immunosuppression
IN Schneider, Heinz; Thurman, Ronald G.
PA Novartis Nutrition A.-G., Switz.; Schneider, Heinz; Thurman, Ronald G.
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9804256	A1	19980205	WO 97-EP4125	19970729
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9737716	A1	19980220	AU 97-37716	19970729
PRAI	US 96-690476	19960730			
	WO 97-EP4125	19970729			

AB The present invention provides for the use of glycine in the prepn. of a medicament or nutritional formulation for the prophylaxis and/or therapy of renal dysfunction induced by cyclosporins or ascomycins. For example, an **enteral** compn. contained water 77.4, maltodextrins 12.28, Na/Ca caseins 4.6, glycine 3, palm **oils** 2.33, sunflower **oils** 0.26, and emulsifier Nathin E 0.13 %.

IT **56-40-6**, Glycine, biological studies **74-79-3**, L-Arginine, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutrient compns. for prevention of renal dysfunctions induced by cyclosporin and ascomycin)

L68 ANSWER 8 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1997:636105 HCAPLUS
DN 127:257623
TI Method for reducing and controlling immunoglobulin concentrations
IN Trimbo, Susan; Madsen, David; Rowe, W. Bruce
PA **Nestec** Ltd., Switz.
SO U.S., 8 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5670157	A	19970923	US 95-570098	19951211

AB The present invention provides a method for reducing and controlling antigen-specific Ig concns. in a patient. In addn., the present invention provides a method for maintaining physiol. functions of the intestine in a patient. The compn. includes a **protein** source, a **carbohydrate** source, a **fat** source, and a specialized vitamin and mineral profile.

L68 ANSWER 9 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1997:576597 HCAPLUS
DN 127:239127
TI Enteral composition for malabsorbing patients
IN Stalker, Lance; **Twyman, Diana**; Chang, Shen-youn; Jaussan, Veronique
PA **Nestec**, Ltd., Switz.
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5661123	A	19970826	US 95-372980	19950117

AB A method for providing nutrition to non-catabolic and moderately catabolic patients is disclosed. Pursuant to the present invention, the enteral compn. includes a peptide based protein source of hydrolyzed **whey**, a **lipid** source, and a **carbohydrate** source. Preferably, the protein source includes approx. 22% to about 27% of the total calories. The compn. has a caloric d. of approx. 1000 Kcal/L and a low osmolality of approx. 300 to 450 mOsm/Kg H2O. Still further, the compn. of the present invention also includes increased levels of certain vitamins and minerals. Formulation of an enteral compn. contg. proteins, **carbohydrates**, **fats**, vitamins, and minerals is disclosed.

L68 ANSWER 10 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1997:532205 HCAPLUS
DN 127:189892
TI Food and vitamin preparations containing the natural isomer of reduced folates
IN Bailey, Steven W.; Ayling, June E.
PA South Alabama Medical Science Foundation, USA; Bailey, Steven W.; Ayling, June E.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9727764	A1	19970807	WO 97-US1870	19970131
	W: AU, CA, CN, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9722602	A1	19970822	AU 97-22602	19970131
	EP 877563	A1	19981118	EP 97-905791	19970131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 96-10898		19960131		
	WO 97-US1870		19970131		

AB A compn. for human or animal consumption for supplying folate which includes a natural isomer of reduced folate, such as (6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5-formyl-(6S)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetrahydrofolic acid, and their polyglutamyl derivs. is disclosed. Such compns. include multivitamin prepns. (with or without minerals and other nutrients); breakfast foods such as prepd. cereals, toaster pastries and breakfast bars; infant formulas; dietary supplements and complete diet and wt.-loss formulas and bars; animal feed (for example pet foods) and animal feed supplements (such as for poultry feed). The amt. of the natural isomer of a reduced folate in a compn. for human consumption can range between about 5 % and about 200 % of the daily requirement for folic acid per serving or dose.

IT **50-81-7**, L-**Ascorbic** acid, biological studies
50-99-7, **Dextrose**, biological studies **56-87-1**, L-Lysine, biological studies **63-68-3**, L-Methionine, biological studies **107-35-7**, **Taurine 541-15-1**, L-**Carnitine 7235-40-7**, .beta.-**Carotene**

7782-49-2, **Selenium**, biological studies
RL: BOC (Biological occurrence); FFD (Food or feed use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(food and vitamin prepns. contg. the natural isomer of reduced folates)

L68 ANSWER 11 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1997:499072 HCAPLUS
DN 127:126660
TI Liquid nutritional product containing improved stabilizer composition of carrageenan/microcrystalline cellulose/CM-cellulose
IN Mulchandani, Rohini Prakash; Mahmoud, Mohamed Ibrahim
PA Abbott Laboratories, USA
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9725878	A1	19970724	WO 97-US1009	19970121
W: CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5700513	A	19971223	US 96-588957	19960119
PRAI US 96-588957		19960119		

AB A liq. nutritional product with improved phys. stability comprises: (a) a liq. nutritional mixt. contg. **fat** at a concn. sufficient to have the liq. nutritional mixt. be susceptible to creaming and contg. suspended minerals present at a concn. sufficient to have the liq. nutritional mixt. be susceptible to sedimentation; (b) a carrageenan/microcryst. cellulose/CM-cellulose additive compn. comprising .iota.-carrageenan (100-800 ppm) and a mixt. of microcryst. cellulose/CM-cellulose (600-3000 ppm). Thus, .iota.-carrageenan (Viscarin SA 359) and a mixt. of microcryst. cellulose/CM-cellulose (Avicel CL 611) may be used at 325 and 1200 ppm, resp.

L68 ANSWER 12 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1997:463612 HCAPLUS
DN 127:113210
TI **Enteral** delivery of insulin in normal humans using an **oil**-based Macrosol formulation
AU New, R.R.C.; Littlewood, G.M.; Cripps, D.; Kirby, C.J.; Guard, P.; Flynn, M.J.
CS Cortecs International Ltd, The Old Blue School, Middlesex, TW7 6RL, UK
SO Proc. Int. Symp. Controlled Release Bioact. Mater. (1997), 24th, 339-340
CODEN: PCRMEY; ISSN: 1022-0178
PB Controlled Release Society, Inc.
DT Journal
LA English
AB Insulin was administered in a Macrosol (medium chain monoglyceride) formulation. Increases in total insulin in blood plasma were obsd. over the 1st 20 min in 5 out of 6 subjects receiving the insulin in Macrosol, at later times, in response to this, the suppression of endogenous secretion of insulin was indicated by the marked redn. in C-**peptide** in the blood. A small redn. in **glucose** was also obsd., presenting a consistent picture of insulin, C-**peptide** and **glucose** changes in accord with those to be expected after administration of exogenous insulin.

L68 ANSWER 13 OF 39 HCAPLUS COPYRIGHT 1999 ACS

AN 1997:397380 HCAPLUS
DN 127:16891
TI Nutritional support of pediatric patients
IN Trimbo, Susan L.; Kruseman, Jan; Kruzel, Chris; **Mark, David A.**; Reddy, Sekhar
PA Societe Des Produits Nestle S.A., Switz.
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9716079	A1	19970509	WO 96-EP4514	19961015
	W: AU, BR, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RO, RU, SG, TR, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5635199	A	19970603	US 95-549559	19951027
	CA 2231525	AA	19970509	CA 96-2231525	19961015
	AU 9672947	A1	19970522	AU 96-72947	19961015
	CN 1200654	A	19981202	CN 96-197842	19961015
	US 5766621	A	19980616	US 97-866135	19970530
PRAI	US 95-549559	19951027			
	WO 96-EP4514	19961015			

AB An enteral compn. for pediatric patients. The compn. is made up of a protein source, a **carbohydrate** source and a **lipid** source. The protein source provides 10% to 14% of the total calories and is in the form of casein and **whey**. The **lipid** source ~~is a mixt. of~~ medium and long chain **triglycerides** or which are ~~least 20% are~~ medium chain **triglycerides**. The compn. may be used for providing nutrition to a pediatric patient; esp. patients suffering from cerebral palsy or recovering from trauma, burns or surgery and having moderate needs for tissue repair.

L68 ANSWER 14 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1997:347093 HCAPLUS
DN 126:316857
TI Diabetic nutritional product having controlled absorption of **carbohydrate**
IN Wilbert, Gregory J.; Keating, Kim R.; Greene, Harry L.; Lee, Yung-Hsiung
PA Bristol-Myers Squibb Company, USA
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 768043	A2	19970416	EP 96-202877	19961015
	EP 768043	A3	19970521		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CA 2187394	AA	19970417	CA 96-2187394	19961008
	AU 9668188	A1	19970424	AU 96-68188	19961015
	JP 09168374	A2	19970630	JP 96-273497	19961016
PRAI	US 95-5468	19951016			

AB Nutritional compn. for use by diabetics contg. a controlled absorbed **carbohydrate** component. The **carbohydrate** component contains a rapidly absorbed fraction such as **glucose** or sucrose,

a moderately absorbed fraction such as certain cooked starches or fructose, and a slowly absorbed fraction such as raw corn starch.

IT **50-81-7**, **Vitamin C**, biological studies
107-35-7, **Taurine 541-15-1**, L-**Carnitine 7235-40-7**, .beta.-**Carotene** **7782-49-2**, **Selenium**, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(diabetic nutritional product having controlled absorption of **carbohydrate**)

IT **50-99-7**, D-**Glucose**, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diabetic nutritional product having controlled absorption of **carbohydrate**)

L68 ANSWER 15 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1997:257509 HCAPLUS
DN 126:237703
TI Nutritional composition
IN Alexander, John; Gray, Debora; **Mark, David A.**; Schmelkin, Nancy; **Twyman, Diana**
PA Clintec Nutrition Company, An Illinois Partnership, USA
SO Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 764405	A2	19970326	EP 96-202637	19960920
	EP 764405	A3	19980429		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5714472	A	19980203	US 95-530877	19950920
PRAI	US 95-530877		19950920		
	US 93-172587		19931223		

AB The present invention provides an enteral nutritional formulation that meets the nutrient requirements of intensive care patients who may have compromised absorption capacity. The present invention meets the unique nutrient needs necessitated by tissue repair and healing requirements. The invention provides nutritional support to intensive care patients comprising the steps of administering a therapeutically effective amt. of a compn. including a **protein** source, a **carbohydrate** source, and a **lipid** source including source of medium chain **triglycerides**, a source of omega-3 **fatty** acids, and a source of omega-6 **fatty** acids.

IT **50-81-7**, **Vitamin c**, biological studies
52-90-4, Cysteine, biological studies **74-79-3**, Arginine, biological studies **107-35-7**, **Taurine 541-15-1**, L-**Carnitine 7235-40-7**, .beta.-**Carotene** **7782-49-2**, **Selenium**, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enteral nutritional compn. for intensive care patients)

L68 ANSWER 16 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1997:189932 HCAPLUS
DN 126:190943
TI Composition for nutrition
IN Windenband, Albrecht; Pausch, Gudrun; Karsten, Simone

PA B. Braun Melsungen Ag, Germany
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DT **Patent**
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 756827	A2	19970205	EP 96-112251	19960730
	EP 756827	A3	19970917		
	R: BE, DE, ES, FR, GB, IT, NL				
	DE 19528461	A1	19970206	DE 95-19528461	19950803
	JP 09121809	A2	19970513	JP 96-200120	19960730
PRAI	DE 95-19528461	19950803			

AB A compn. for **enteral** or oral nutrition of patients with immune deficiencies, immune diseases, tumors, inflammatory, or other disorders comprises **protein** or **protein** hydrolyzate, **carbohydrate**, **fat**, fiber, and water, the **fat** content being 20-30 energy percent and consisting of medium-chain **triglycerides** 30-70, n-3/n-6 **fatty** acids 1-3.1 to 1-7 ratio, n-6/n-9 **fatty** acids 1-0.7 to 1-1.4 ratio, simple unsatd. **fatty** acids/polyunsatd. **fatty** acids ratio of 1-0.5 to 1-1.5, and the **protein** component contains 0.5-3.0 g glutamine/100 mL.
IT **52-90-4**, Cysteine, biological studies **56-85-9**, Glutamine, biological studies **74-79-3**, Arginine, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**enteral**/oral feeding compn. for human nutrition)

L68 ANSWER 17 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1997:42018 HCAPLUS
DN 126:65460
TI Enteral composition for treating renal failure
IN Chang, Shen-Youn; Madsen, Dave C.; Trimbo, Susan L.; Tucker, Hugh N.; **Twyman, Diana**
PA Clintec Nutrition Company, An Illinois Partnership, USA
SO Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 747395	A1	19961211	EP 96-201536	19960604
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5728678	A	19980317	US 95-470985	19950606
	CA 2177195	AA	19961207	CA 96-2177195	19960523
	JP 09020678	A2	19970121	JP 96-141368	19960604
PRAI	US 95-470985	19950606			

AB The invention provides an enteral compn. for providing nutrition to renal patients. The enteral compn. includes an effective amt. of a protein source including **whey** protein and free amino acids that provide essential as well as nonessential amino acids. The compn. is calorically dense and has a moderate osmolality.

L68 ANSWER 18 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1996:546569 HCAPLUS

DN 125:257178
TI Enteral nutrient compositions for pediatric patients
IN **Mark, David A.**; **Twyman, Diana**; Buckley, Donna
PA Clintec Nutrition Co., USA
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5549905	A	19960827	US 94-324727	19941018

AB The present invention provides a method and nutritional compn. for providing nutrition to pediatric patients with impaired nutrient absorption and/or reduced gastrointestinal tolerance. The enteral compn. includes a hydrolyzed **protein** source comprising .apprx.12% of the total calories, a **carbohydrate** source and a **lipid** source comprising a mixt. of medium- and long-chain **triglycerides**, wherein .gtoreq.55% of the **lipid** source are medium-chain **triglycerides**. The compn. includes **whey** (as **protein** source); maltodextrin, sucrose, corn starch (as **carbohydrate** source); safflower **oils**, canola **oils**, soy **oils**, coconut **oil**, residual milk **fat**, soy lecithin (as **lipid** source); water; vitamins (vitamin A, B1, B2, B6, B12, D, E, K, and C, .beta.-**carotene**, folic acid, pantothenic acid, biotin); choline; **taurine**; L-**carnitine**; inositol, Ca, P, Mg, **Zn**, Fe, Cu, Mn, I2, Na, K, Cl, Cr, Mo, and **Se**.
IT **50-81-7**, **Vitamin C**, biological studies
107-35-7, **Taurine 541-15-1**, L-**Carnitine 7235-40-7**, .beta.-**Carotene**
7782-49-2, **Selenium**, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**proteins** and **lipids** and **carbohydrates** and minerals and vitamins in enteral nutrient compns. for pediatric patients)

L68 ANSWER 19 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1996:473322 HCAPLUS
DN 125:113594
TI Nutrition for elderly patients
IN Chang, Shen-Youn; Kruzel, Chris; Lin, Paul
PA Clintec Nutrition Company, An Illinois Partnership, USA
SO Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 721742	A1	19960717	EP 96-200047	19960110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5589468	A	19961231	US 95-372558	19950113
CA 2166003	AA	19960714	CA 95-2166003	19951222
AU 9540765	A1	19960725	AU 95-40765	19951229
JP 08231411	A2	19960910	JP 96-1951	19960110
US 5686429	A	19971111	US 96-768204	19961217

PRAI US 95-372558 19950113
AB This provides a compn. and method for providing nutrition to elderly

patients. The compn. includes a **protein** source providing at least 16% of the calories of the compn., a **lipid** source, and a **carbohydrate** source. The **carbohydrate** source includes a source of dietary fiber including a balance of sol. to insol. fiber ratio of approx. 1:3. The compn. also includes increased levels of certain vitamins and minerals.

IT **50-81-7**, **Vitamin C**, biological studies
107-35-7, **Taurine** **541-15-1**, **Carnitine**
7235-40-7, .beta.-**Carotene** **7782-49-2**,
Selenium, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(nutrition formula for elderly patients)

L68 ANSWER 20 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1996:256712 HCAPLUS
DN 124:298974
TI **Enteral** pharmaceuticals containing nutrients to promote wound healing
IN Zaloga, Gary P.; Roberts, Pamela
PA Wake Forest University, USA
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9602137	A1	19960201	WO 95-US8834	19950717
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UZ				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5656588	A	19970812	US 94-276955	19940719
	CA 2195120	AA	19960201	CA 95-2195120	19950717
	AU 9530091	A1	19960216	AU 95-30091	19950717
PRAI	US 94-276955	19940719			
	WO 95-US8834	19950717			

AB The present invention provides a compn. that stimulates and improves wound healing in a patient in need of same. A method for stimulating wound healing comprises the step of administering to a patient a compn. including a therapeutically effective amt. of a source of carnosine. The compn. also meets the nutrient requirements of a patient that are generated due to tissue repair and healing requirements. For example, a compn. contained **proteins** (arginine and carnosine sources) 20-35, **lipids** (MCT **oils**, sunflower **oils**, or soy **oils**) 20-40, and **carbohydrates** (maltodextrin or starch) 30-50% of calories. The compn. further contained vitamin C, vitamin E, vitamin A, and Zn.

IT **74-79-3**, Arginine, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**enteral** pharmaceuticals contg. nutrients to promote wound healing)

L68 ANSWER 21 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1996:239929 HCAPLUS

DN 124:270592
TI Composition for the treatment of intestinal wounds or ulcers containing **proteins**, **carbohydrates** and **fats**
IN Leddin, Desmond
PA Dalhousie University, Can.
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 699444	A2	19960306	EP 95-306124	19950901
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5578576	A	19961126	US 94-300428	19940902
	AU 9530407	A1	19960314	AU 95-30407	19950901
	JP 08188536	A2	19960723	JP 95-226572	19950904
PRAI	US 94-300428	19940902			

AB The invention relates to the manuf. of a therapeutic compn. for aiding healing or preventing the onset of intestinal wounds or ulcers in a patient, reducing, or preventing the gastrointestinal side effects assocd. with the administration of a nonsteroidal anti-inflammatory drug or treatment of arthritis. The compn. includes a **protein** source, a **carbohydrate** source, and a **fat** source, and may include vitamins and minerals. For example, a com. available Peptamen contg. maltodextrin, hydrolyzed **whey protein**, fractionated coconut **oil**, corn starch, minerals, and vitamins was suitable compn. for this purpose. The product was tested for healing of indomethacin-induced ulceration in rats.

L68 ANSWER 22 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1996:13270 HCAPLUS
DN 124:66633
TI **Enteral** diet and method for providing nutrition to a diabetic
IN Laughlin, Philip; Alexander, John; Kamarei, A. Reza; Dobbie, Robert P.; Lin, Paul; Chang, Shen Youn; Reddy, Sekhar; Grasset, Etienne; Melin, Christian
PA Clintec Nutrition Co., USA
SO U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 51,632, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5470839	A	19951128	US 94-271114	19940706
	CA 2153348	AA	19960107	CA 95-2153348	19950706
	EP 691079	A2	19960110	EP 95-201852	19950706
	EP 691079	A3	19960724		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08067630	A2	19960312	JP 95-203739	19950706
	AU 9524950	A1	19960118	AU 95-24950	19950707
	AU 698606	B2	19981105		
PRAI	US 93-51632	19930422			
	US 94-271114	19940706			

AB A compn. and method for providing nutrition or a nutritional supplement to a diabetic patient, are described. A low **carbohydrate**, high **fat enteral** formulation comprises (1) a **protein** source, (2) a **carbohydrate** source including a slowly digested

high-amylose starch component, and (3) a **fat** source that includes medium-chain **triglycerides** and has an n-6:n-3 ratio of .ltoreq.10. Preferably, the compn. includes a high percent of mono-unsatd. **fats**, high amylose starch, and sol. dietary fiber. The compn. is administered to the diabetic patient through a nasogastric tube.

L68 ANSWER 23 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1995:795198 HCAPLUS
DN 123:179519
TI Method of enhancing the human immune system
IN Masor, Marc Leif; Hilty, Milo Duane
PA Abbott Laboratories, USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9518547	A1	19950713	WO 95-US85	19950105
	W: AU, CA, JP, MX, NZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5602109	A	19970211	US 94-178686	19940110
	CA 2180465	AA	19950713	CA 95-2180465	19950105
	AU 9515977	A1	19950801	AU 95-15977	19950105
	EP 739169	A1	19961030	EP 95-907976	19950105
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10507439	T2	19980721	JP 95-518576	19950105
PRAI	US 94-178686	19940110			
	WO 95-US85	19950105			

AB An improved **enteral** nutritional formula contg. nucleotide equiv. (RNA, mono-, di- and triphosphate nucleotides, nucleosides and adjuncts such as activated sugars) at a level of at least 10 mg/100 Kcal of formula is disclosed. The formula comprises **carbohydrates**, **lipids**, **proteins**, vitamins and minerals and four (4) nucleotide equiv. at specific levels and ratios. The invention also discloses novel methods of prodn. and anal. techniques. This invention also provides a dietary formula that enhances the immune system and alleviates diarrhea.

L68 ANSWER 24 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1995:731857 HCAPLUS
DN 123:123203
TI **Enteral** nutritional composition
IN Kvamme, Candis; Schmidl, Mary K.
PA USA
SO Can. Pat. Appl., 23 pp.
CODEN: CPXXEB
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2133783	AA	19950409	CA 94-2133783	19941006
	CA 2133783	C	19970923		
	US 5438042	A	19950801	US 93-134226	19931008
	US 5438042	B1	19970826		
	US 5504072	A	19960402	US 95-387038	19950210

US 5504072 B1 19970826
PRAI US 93-134226 19931008
AB An **enteral** nutritional compn. comprising 4-30% **lipid** component, 65-80% **carbohydrate** component and 16-25% **protein** component, based on total caloric content, wherein said **protein** comprises by wt. 14-30% glutamine and 5-33% arginine and said compn. has a nonprotein calorie to grams of nitrogen ration of 150:1 to 80:1.
IT **56-85-9**, Glutamine, biological studies **74-79-3**, Arginine, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**enteral** nutritional compn.)

L68 ANSWER 25 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1995:655223 HCAPLUS
DN 123:40967
TI Compositions and their use for retarding the aging process
IN Kamerei, Ahmad Reza; Goldberg, Dennis I.; **Mark, David A.**; Pace, Gary
PA Free Radical Sciences, Inc., USA
SO Eur. Pat. Appl., 7 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 655245	A2	19950531	EP 94-308005	19941031
R: CH, DE, ES, FR, GB, IT, LI, SE				
AU 9475969	A1	19950518	AU 94-75969	19941021
CA 2134707	AA	19950502	CA 94-2134707	19941031
JP 07188018	A2	19950725	JP 94-266779	19941031

PRAI US 93-146305 19931101
AB Compns., diets and regimens are disclosed for maintaining intracellular levels of glutathione at sufficient levels to prevent oxidative and free radical damage to the cells, so as to retard the aging process in mammals. A diet, regimen, or nutritional compn. for reducing agent in a person comprises 15-30% of the calories from cysteine-rich protein, 15-25% of the calories from **lipids**, 45-70% of the calories from **carbohydrates**, and vitamin/mineral mixts. meeting or exceeding USRDA values in 1000 or 2000 cal of the product.

L68 ANSWER 26 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1994:541707 HCAPLUS
DN 121:141707
TI Medical foods for the nutritional support of infant/toddler metabolic diseases
IN Acosta, Phyllis Jean Brown; Grondalski, Richard Andrew; Liebrecht, Jeffrey Wayne; Reynolds, Patricia Ann
PA Abbott Laboratories, USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9414458	A1	19940707	WO 93-US10866	19931110
W: AU, CA, JP, KR, NZ				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU	9455991	A1	19940719	AU 94-55991	19931110
AU	679020	B2	19970619		
EP	675725	A1	19951011	EP 94-901392	19931110
	R: DE, ES, FR, GB, IE, IT, NL				
CA	2143420	C	19990119	CA 93-2143420	19931110
US	5587399	A	19961224	US 94-230452	19940420
US	5550146	A	19960827	US 95-423177	19950418
PRAI US	92-997278	19921223			
WO	93-US10866	19931110			
US	94-230452	19940420			

AB A novel generic powder base rich in **fats**, **carbohydrates**, vitamins, minerals and trace elements is readily admixed with specific amino acids to yield several different therapeutic products for use in nutritional support of infant/toddlers having various inherited metabolic diseases.

IT **61-90-5**, Leucine, biological studies
RL: BIOL (Biological study)
(catabolic disorders, treatment of, nutritional supports rich in **fats** and **carbohydrates** and vitamins and minerals for)

IT **63-91-2**, Phenylalanine, biological studies
RL: BIOL (Biological study)
(metabolic disorders, hyperphenylalaninemia, treatment of, nutritional supports rich in **fats** and **carbohydrates** and vitamins and minerals for)

IT **60-18-4**, Tyrosine, biological studies
RL: BIOL (Biological study)
(metabolic disorders, tyrosinemia type 1, treatment of, nutritional supports rich in **fats** and **carbohydrates** and vitamins and minerals for)

IT **50-99-7**, **Dextrose**, biological studies **56-40-6**, Glycine, biological studies **56-41-7**, Alanine, biological studies **56-45-1**, Serine, biological studies **56-84-8**, Aspartic acid, biological studies **56-85-9**, Glutamine, biological studies **56-86-0**, Glutamic acid, biological studies **56-87-1**, L-Lysine, biological studies **63-68-3**, Methionine, biological studies **71-00-1**, Histidine, biological studies **72-18-4**, Valine, biological studies **72-19-5**, Threonine, biological studies **73-22-3**, L-Tryptophan, biological studies **73-32-5**, Isoleucine, biological studies **74-79-3**, Arginine, biological studies **147-85-3**, Proline, biological studies
RL: BIOL (Biological study)
(nutritional compns. contg., for infants and toddlers with metabolic diseases)

IT **50-81-7**, **Ascorbic** acid, biological studies **107-35-7**, **Taurine** **541-15-1**, **Carnitine** **7235-40-7**, .beta.-**Carotene** **7782-49-2**, **Selenium**, biological studies
RL: BIOL (Biological study)
(nutritional premix. compns. contg., for infants and toddlers with metabolic diseases)

L68 ANSWER 27 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1994:173506 HCAPLUS
DN 120:173506
TI Nutritional product for persons having a neurological injury
IN Garleb, Keith Allen; Demichele, Stephen Joseph; Rausch, Linda Sue; Fuller, Martha Kay; Behr, Stephen Richard

PA Abbott Laboratories, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9402166	A1	19940203	WO 93-US6005	19930623
	W: AT, AU, BR, CA, FI, JP, NO, NZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5308832	A	19940503	US 92-920087	19920727
	JP 07507327	T2	19950810	JP 93-504464	19930623
	AU 666246	B2	19960201	AU 94-55747	19930623
PRAI	US 92-920087	19920727			
	WO 93-US6005	19930623			

AB An enteral nutritional product for a person having a neurol. injury is very low in **carbohydrate**, but high in **fat** and has a viscosity suitable for tube feeding. The **fat** is supplied by a **lipid** blend having a ratio of n-6 to n-3 **fatty** acids in the range of 1 to 6. Preferably, the nutritional product contains nutrients having antioxidant properties, for example .beta.-**carotene**, vitamin E, **vitamin C**, **taurine**, Mo, and **Se**. For example, a formulation for head trauma contained medium-chain **triglycerides** 5.80, refined sardine **oil** (with high concn. of .omega.-3 **fatty** acids) 2.46, canola **oil** 6.62, borage **oil** 2.46, high-oleic acid safflower **oil** 5.88, acid casein 20.3 lb, soy lecithin 552, 20% NaOH 955, K citrate 223, Mg phosphate 185, CaCO3 231, MgCl2 92.5, Ca3(PO4)2 17.9, KCl 204, Na citrate 19.7, mineral premix (contg. **Zn**, Fe, Mn, Cu, **Se**, Cr, and Mo) 28.3, KI 0.0218, **oil**-sol. vitamin premix (contg. vitamin A palmitate, vitamin D, DL-.alpha.-tocopheryl acetate, and phylloquinone) 6.94, DL-.alpha.-tocopheryl acetate 23.1, **ascorbic** acid 60, water-sol. vitamin premix (contg. niacinamide, Ca pantothenate, pyridoxine.cntdot.HCl, thiamin.cntdot.HCl, riboflavin, folic acid, biotin, cyanocobalamine) 12,8, **taurine** 17.6, **carnitine** 8.8, choline chloride 42.0g, and water 151 lbs.

IT **50-81-7**, **Vitamin c**, biological studies
107-35-7, **Taurine 7235-40-7**, .beta.-**Carotene 7782-49-2**, **Selenium**, biological studies
RL: BIOL (Biological study)
(enteral nutritional compns. for neurol. injury patients contg., high-**fat**)

L68 ANSWER 28 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1993:656552 HCAPLUS
DN 119:256552
TI Improved high-**protein** liquid nutrition for patients with elevated wound healing requirements
IN Trimbo, Susan L.; Twyman, Diana
PA Clintec Nutrition Co., USA
SO Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	EP 564804	A1	19931013	EP 93-103174	19930227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9333745	A1	19940414	AU 93-33745	19930224
	CA 2093453	AA	19931011	CA 93-2093453	19930406
	JP 06048954	A2	19940222	JP 93-84352	19930412
PRAI	US 92-866833	19920410			

AB Nutrients for patients with elevated wound healing requirements due to trauma, burns, pressure ulcers, post-surgical wound care, cancer, and repletion of lean body mass losses .gtoreq.15%, comprises **proteins**, **fats**, **carbohydrates**, **Zn**, **vitamin C**, **Se**, vitamin A, and thiamine. A compn. (1000 kcal) contained **protein** 62.5, **fat** 34.0, MCT **oil** 8.4, canola **oil** 23.6, lecithin 2.0, **carbohydrate** 113, water 845 g, vitamin A 7333, vitamin D 400, vitamin E 60 IU, vitamin K 80 .mu.g, **vitamin C** 340, thiamine 3, riboflavin 2.4, niacin 28, vitamin B6 4mg, folic acid 540, vitamin B12 8, biotin 400 .mu.g, pantothenic acid 14, choline 450, **taurine** 100, L-**carnitine** 100, Ca 1000, P 1000, Mg 400, Fe 18, **Zn** 24, Cu 2, Mn 4, Na 500, K 1560, Cl 1000 mg, I 160, Cr 140, Mo 220, and **Se** 100 .mu.g.

IT **50-81-7**, **Vitamin C**, biological studies
107-35-7, **Taurine 541-15-1**, L-**Carnitine 7235-40-7**, .beta.-**Carotene**
7782-49-2, **Selenium**, biological studies
RL: BIOL (Biological study)
(high-**protein** liq. nutrients for elevated wound healing requirements contg.)

L68 ANSWER 29 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1993:516007 HCAPLUS
DN 119:116007
TI Low caloric density enteral formulation designed to reduce diarrhea in tube-fed patients
IN **Mark, David A.**; Stalker, Lance
PA Clintec Nutrition Co., USA
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PI	US 5229136	A	19930720	US 92-887361	19920521
	CA 2095889	AA	19931122	CA 93-2095889	19930510
	EP 570791	A2	19931124	EP 93-107543	19930510
	EP 570791	A3	19950329		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9338519	A1	19931125	AU 93-38519	19930512
	JP 06056693	A2	19940301	JP 93-119714	19930521
PRAI	US 92-887361	19920521			

AB An enteral feeding formulation with a caloric content of <1.0 Kcal/mL, an osmolality <300 mOsm and a fiber content >15 g/L is described for use in the control of diarrhea in enterically fed patients. Protein supplies 18-25% of calories and **fat** 35-50%.

L68 ANSWER 30 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1993:415346 HCAPLUS
DN 119:15346

TI **Enteral** preparation for cancer therapy
IN Aoi, Shozo; Ebisu, Goro
PA Otsuka Pharmaceutical Factory, Inc., Japan
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT **Patent**
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9306834	A1	19930415	WO 92-JP1264	19920930
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	CA 2097196	AA	19930408	CA 92-2097196	19920930
	AU 9226913	A1	19930503	AU 92-26913	19920930
	AU 651738	B2	19940728		
	EP 560989	A1	19930922	EP 92-920732	19920930
	R: AT, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	JP 2743119	B2	19980422	JP 92-506782	19920930
	US 5658895	A	19970819	US 95-468332	19950606
PRAI	JP 91-258883	19911007			
	WO 92-JP1264	19920930			
	US 93-66138	19930527			

AB An **enteral** prepn. for cancer therapy contains amino acids, **fats** and sugars in a specified compn. This prepn. allows smooth oral and **enteral** administration to achieve alimentation for patients with cancer and inhibition of the growth of cancer cells. When used together with a carcinostatic agent, it can potentiate the antitumor effect of the carcinostatic agent synergistically. For an **enteral** prepn. manuf., 754 g total amino acids in 5000 mL was heated at 70-80.degree., and mixed with 10 g soybean lecithin in 222 g soybean **oil** and 30 g sucrose **fatty** acid esters in 1 mL distd. water. The mixt. was dried to form a powder, 510 g of the powder was granulated with dextrin and homogenized with an appropriate amt. of mineral, and vitamins, and the resultant product was filled into containers. The product was dissolved, administered intragastrically at 300 mL/kg to rats bearing Yoshida sarcoma. 5-FU (10 mg/kg/day) was administered to the rats on day 1, 2, 3, 4, 5, and 6 of the intragastric treatment. Decrease of the wt. of Yoshida sarcoma was greater than that in controls given 5-FU alone.

IT **56-40-6**, Glycine, biological studies **56-41-7**, Alanine, biological studies **56-45-1**, Serine, biological studies **56-84-8**, Aspartic acid, biological studies **56-85-9**, Glutamine, biological studies **56-86-0**, Glutamic acid, biological studies **56-87-1**, Lysine, biological studies **60-18-4**, Tyrosine, biological studies **61-90-5**, Leucine, biological studies **63-91-2**, Phenylalanine, biological studies **70-47-3**, L-Asparagine, biological studies **71-00-1**, Histidine, biological studies **72-18-4**, L-Valine, biological studies **72-19-5**, Threonine, biological studies **73-22-3**, Tryptophan, biological studies **73-32-5**, Isoleucine, biological studies **74-79-3**, Arginine, biological studies **147-85-3**, Proline, biological studies
RL: BIOL (Biological study)
(enteric pharmaceutical dosage forms contg., for cancer therapy)

L68 ANSWER 31 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1991:606493 HCAPLUS
DN 115:206493

TI Quantitative determination of complex **carbohydrates** in bovine milk and in milk-based infant formulas
AU Neeser, Jean Richard; Golliard, Mireille; Del Vedovo, Simone
CS Nestle Res. Cent., **Nestec** Ltd., Lausanne, CH-1000, Switz.
SO J. Dairy Sci. (1991), 74(9), 2860-71
CODEN: JDSCAE; ISSN: 0022-0302
DT Journal
LA English
AB Quant. detn. of all structural families of complex **carbohydrate** micronutrients was performed on bovine milk samples., milk-based infant formulas, and **whey**-based manufg. raw materials. Differences found between formulas depended mainly on their **whey**/casein ratios. A solvent sepn. procedure was required for quant. estn. of the gangliosides and neutral **glycolipids** within the **fat** fraction. All infant formulas except one contained slightly more gangliosides than bovine milk. Complex **carbohydrates** were consistently higher in the nonfat fraction. Gel permeation chromatog. sepd. an **oligosaccharide** subfraction from a glycopeptide one. The **oligosaccharide** content of infant formulas increased as a function of the **whey**/casein ratio, and glycopeptides were found only in formulas made with **whey** components. Neuraminic acids from infant formulas were assocd. primarily with the glycoprotein fraction, except in hydrolyzate-based prepns. in which "precipitable" glycoproteins were converted into "sol." glycopeptides by trypsin treatment. Because **whey**-based raw materials are very rich in all bovine milk glycoconjugates and **oligosaccharides**, their increased use will result in high contents of these micronutrients in modern formulas.

L68 ANSWER 32 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1990:558713 HCAPLUS
DN 113:158713
TI **Enteral** nutrient formulations under stressful physiological conditions
IN Kashiwabara, Norio; Hayashi, Naoki
PA Snow Brand Milk Products Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02134326	A2	19900523	JP 88-287078	19881114

PI JP 02134326 A2 19900523 JP 88-287078 19881114
AB A nutrient for enteric administration during a stressful condition contains **peptides** 10-30, branched amino acids (valine, leucine, and isoleucine) 3-10, mid-chain **fatty** acid **triglyceride** -edible **oil** 4-10, and sugars 50-80% by wt. (total N content 2-5% by wt.; nonprotein calorie/N = 75-120). A nutrient compn. consisted of **protein** hydrolyzate 17.26, L-methionine 0.38, L-tryptophan 0.09, L-leucine 2.35, L-isoleucine 1.14, L-valine 0.97, **triglycerides** 2.64, safflower **oil** 1.13, lecithin 0.96 and dextrin 69.32% by wt.
IT **61-90-5**, L-Leucine, biological studies **72-18-4**, L-Valine, biological studies **73-32-5**, L-Isoleucine, biological studies
RL: BIOL (Biological study)
(**enteral** nutrient formulations contg.)

L68 ANSWER 33 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1989:121440 HCAPLUS
DN 110:121440
TI **Enteral** pharmaceuticals containing omega-3 **fatty** acids for the administration during treatment of traumatic injuries and the related hypermetabolic response
IN Alexander, J. Wesley
PA Shriners Hospitals for Crippled Children, USA
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8806035	A1	19880825	WO 88-US504	19880219
	W: AU, BR, DK, FI, JP, NO				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8814896	A1	19880914	AU 88-14896	19880219
	EP 310639	A1	19890412	EP 88-902675	19880219
	EP 310639	B1	19930303		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 86108	E	19930315	AT 88-902675	19880219
	CA 1316457	A1	19930420	CA 88-560766	19880307
	US 5053387	A	19911001	US 90-524667	19900516
PRAI	US 87-17326	19870220			
	US 87-2035	19870112			
	EP 88-902675	19880219			
	WO 88-US504	19880219			
	US 89-298825	19890118			
	US 89-418690	19891002			

AB **Enteral** compns. contain an intact **protein**, vitamin A in amts. sufficient to prevent diarrhea, **carbohydrates**, and **lipids**. **Protein**, **carbohydrates**, and **lipids** comprise amts. that represent 20-30%, 65-70, and 7-15% by wt. of the total energy intake. The **lipids** comprise sufficient linoleic acid to prevent an essential **fatty** acid deficiency and .omega.-3 **fatty** acids of fish **oil** including eicosapentaenoic acid in an amt. sufficient to reduce a hypermetabolic resting metabolic state assocd. with traumatic injury. An **enteral** compn. contained 750 mL H2O, 6 mL MaxEPA (fish **oil**), 9 mL **Microlipid** (safflower **oil**), 62 g Promix, 149 g Sumacal (**carbohydrates**), 5 g arginine-HCl, 1 g histidine, 1 g cysteine, 24 g Nutrisource minerals, 20 g Nutrisource vitamins, and 0.1 mL vitamin A (50,000 units/mL). This compn. provided 1021 kcal. In burn patients a relationship between dietary **lipid** intake and the incidence of diarrhea related to **enteral** feeding was established.
IT **52-90-4**, Cysteine, biological studies **71-00-1**, Histidine, biological studies **74-79-3**, Arginine, biological studies
RL: BIOL (Biological study)
(**enteral** nutrient compn. contg. fish **oil** and linoleic acid and, for treatment of trauma-induced hypermetabolic state)

L68 ANSWER 34 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1989:121401 HCAPLUS
DN 110:121401
TI **Enteral** and parenteral nutrients containing linoleinc

acid-containing **glycerides** for the treatment of atherosclerotic, vascular, cardiovascular, and/or thrombotic diseases

IN Cotter, Richard; Johnson, Robert C.; Ward, Michael; Madsen, David C.; Valicenti, Anthony J.; Menard, Michael P.; Tucker, Hugh N.

PA Baxter Travenol Laboratories, Inc., USA

SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2

DT **Patent**

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8801861	A1	19880324	WO 87-US2347	19870916
	W: AU				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8781520	A1	19880407	AU 87-81520	19870916
	AU 596880	B2	19900517		
	EP 283513	A1	19880928	EP 87-907043	19870916
	EP 283513	B1	19930428		
	R: AT, BE, CH, DE, FR, GB, IT, LI				
	AT 88631	E	19930515	AT 87-907043	19870916
	CA 1318172	A1	19930525	CA 87-547086	19870916
	US 4920098	A	19900424	US 89-403849	19890828
PRAI	US 86-908447	19860917			
	EP 87-907043	19870916			
	WO 87-US2347	19870916			

AB A nutritional compn. for **enteral** or parenteral administration to patients under treatment for or at risk of atherosclerotic, vascular, cardiovascular, and/or thrombotic disease comprises nutritionally effective amts. of **proteins**, **carbohydrates**, medium chain **fatty** acids, and **lipids** selected from gamma-linolenic acid, sterodonic acid, and marine **oil**. The **protein** source included lactalbumin, L-carnitine, enhanced branched-chain amino acids, arginine and lysine at a high Arg:Lys ratio, and glycine. An **enteral** formulation providing 2.0 kcal/mL contained: (1) 100 g/L **protein** (20% of calories); (1) **carbohydrates** such as maltodextrin 121, xylitol 121, ribose 8 g/L (50% of calories); (3) a **fat** source comprising marine **oil**, .gamma.-linolenic acid, and medium chain **triglycerides** in a 3:1:12 ratio (30% of calories); and (4) electrolytes comprising Na 500, K 1000, Cl 1000, Ca 1200, P 1000, and Mg 60 mg/L.

IT **50-99-7**, **Glucose**, biological studies **56-40-6**, Glycine, biological studies **56-41-7**, Alanine, biological studies **56-45-1**, Serine, biological studies **56-87-1**, L-Lysine, biological studies **60-18-4**, Tyrosine, biological studies **61-90-5**, Leucine, biological studies **63-68-3**, Methionine, biological studies **63-91-2**, Phenylalanine, biological studies **72-18-4**, Valine, biological studies **72-19-5**, Threonine, biological studies **73-22-3**, L-Tryptophan, biological studies **73-32-5**, Isoleucine, biological studies **74-79-3**, Arginine, biological studies **147-85-3**
, Proline, biological studies
RL: BIOL (Biological study)
(parenteral or **enteral** nutrients contg. linolenic acid-contg. **glycerides** and, for treatment of cardiovascular and thrombotic diseases)

IT **71-00-1**, Histidine, biological studies
RL: BIOL (Biological study)

(parenteral or **enteral** nutrients contg. linolenic acid-contg. **lipids** and, for treatment of cardiovascular and thrombotic diseases)

L68 ANSWER 35 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1988:44032 HCAPLUS
DN 108:44032
TI Targeted **enteral** delivery system containing absorption promoters, for **proteins**, **peptides**, and antibiotics
IN Davies, John Desmond; Touitou, Elka; Rubinstein, Arnold
PA Scherer, R. P., Corp., USA
SO Eur. Pat. Appl., 41 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 225189	A2	19870610	EP 86-309305	19861128
	EP 225189	A3	19871216		
	EP 225189	B1	19921007		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 62195324	A2	19870828	JP 86-282174	19861128
	JP 2633843	B2	19970723		
	AT 81287	E	19921015	AT 86-309305	19861128
	ES 2035821	T3	19930501	ES 86-309305	19861128
PRAI	IL 85-77186		19851129		
	EP 86-309305		19861128		

AB Enteric coated capsules contain **proteins** or .beta.-lactam antibiotics as active ingredients, esp. insulin, and arom. carboxylic acid, ester, or amide promoters. The combination of enteric coating and the promoter permits oral administration of compds. which were previously only available by injection. Drug release occurs in the lower gastrointestinal tract. Porcine insulin 8 IU, Na laurate 4, cetyl alc. 16, and arachis **oil** to 100 mg were filled into soft gelatin capsules made of gelatin 57.65, glycerin 28.95, silicone **oil** 13.14 and K sorbate 0.26 wt.%. The capsules were coated with Eudragit RS and Eudragit S in a 4:6 ratio. At 59 IU/kg orally in rats, these capsules reduced blood **glucose** by 45%, with the max. redn. occurring after 3 h, compared with 58% **glucose** redn. and max. redn. after 2 h, for i.p. injection of 15 IU/kg.

L68 ANSWER 36 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1987:464869 HCAPLUS
DN 107:64869
TI Nutritional **fat** suitable for **enteral** and parenteral products
IN Jandacek, Ronald James; Volpenhein, Robert Anthony
PA Procter and Gamble Co., USA
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 216419	A2	19870401	EP 86-201525	19860905
	EP 216419	A3	19890329		
	EP 216419	B1	19920415		

R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

US	4753963	A	19880628	US 85-780473	19850926
IL	79832	A1	19900610	IL 86-79832	19860825
AT	74718	E	19920515	AT 86-201525	19860905
CA	1292145	A1	19911119	CA 86-518670	19860919
ZA	8607269	A	19870527	ZA 86-7269	19860924
AU	8663157	A1	19870402	AU 86-63157	19860926
AU	592113	B2	19900104		
JP	62129389	A2	19870611	JP 86-227899	19860926
PRAI US	85-780473	19850926			
EP	86-201525	19860905			

AB A nutritional **fat** contains 50-100 wt % **triglycerides** of formula CH2OR1CHOR2CH2OR1 (R1 = n-heptanoyl, n-octanoyl, n-nonanoyl, n-decanoyl, n-undecanoyl; R2 = satd. acyl groups selected from n-heptanoyl, n-octanoyl, n-nonanoyl, n-decanoyl, n-undecanoyl, lauroyl, myristoyl, palmitoyl, stearoyl, oleoyl, linoleoyl, and linolenoyl). An **enteral** feeding compn. might contain 11 minerals, 14 vitamins, **carbohydrate** 200, **protein** 21, and nutritional **fat** 25 g/L, and a parenteral feeding compn. the same vitamins and minerals, lecithin 10, glycerol 2.25, and nutritional **fat** 25 g/L.

IT **50-99-7**, **Glucose**, biological studies
RL: BIOL (Biological study)
(**enteral** feeding compn. contg. amino acids and **fats** and)

L68 ANSWER 37 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1986:539661 HCAPLUS
DN 105:139661
TI Mixture for **enteral**-probe nutrition
IN Tamazashvili, T. Sh.; Kutubidze, A. I.; Popova, T. S.; Gal'perin, Yu. M.; Tamazashvili, M. Sh.; Golovnya, R. V.; Yakovleva, V. N.
PA Moscow Institute of First Aid, USSR; Tbilisi State Medical Institute; Institute of Heteroorganic Compounds, Academy of Sciences, USSR
SO U.S.S.R.
From: Otkrytiya, Izobret. 1986, (23), 6.
CODEN: URXXAF
DT **Patent**
LA Russian
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 1238761	A1	19860623	SU 82-3550131	19821112

AB A mixt. for **enteral**-probe nutrition contg. **proteins**, **fats**, **carbohydrates**, NaCl, CaCl2, KCl and distd. H2O prevents postoperative pancreatitis by adding NaH2PO4 and NaOAc, by using starch and syrup as **carbohydrates**, egg white as **protein**, and aminopeptide and a 20% **fatty** emulsion as **fats**. The compn. of the mixt. is NaH2PO4 2.2-2.7, NaCl 3.25-3.6, NaOAc 2.41-3.1, KCl 1.36-1.65, CaCl2 0.08-0.81, starch 16.5-18.9, syrup 8.1-9.2, egg white 14.3-17.5, amino **peptide** 0.18-0.26, a 20% **fatty** emulsion 0.14-0.16 g/L, the balance being distd. H2O.

L68 ANSWER 38 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1986:539639 HCAPLUS
DN 105:139639
TI **Enteral** nutritional hypoallergenic formula
IN Mahmoud, Mohamed T.
PA Abbott Laboratories, USA

SO Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DT **Patent**
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 189161	A2	19860730	EP 86-100680	19860120
EP 189161	A3	19880914		
EP 189161	B1	19910724		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
IL 77630	A1	19890630	IL 86-77630	19860117
ZA 8600415	A	19860924	ZA 86-415	19860120
AT 65406	E	19910815	AT 86-100680	19860120
AU 8652551	A1	19860807	AU 86-52551	19860121
AU 587414	B2	19890817		
DK 8600415	A	19860730	DK 86-415	19860128
ES 551348	A1	19870101	ES 86-551348	19860128
JP 61180715	A2	19860813	JP 86-15998	19860129
JP 07072127	B4	19950802		
CA 1271360	A1	19900710	CA 86-500630	19860129
PRAI US 85-695993	19850129			
EP 86-100680	19860120			

AB An improved **enteral** nutritional hypoallergenic formula is disclosed. The formula contains **carbohydrates**, **lipids**, **protein** hydrolyzate, vitamins and minerals and a starch modified by octenyl succinic anhydride which is utilized as the sole **lipid** emulsifying agent to provide a nutritionally well-balanced dietary formula.

L68 ANSWER 39 OF 39 HCAPLUS COPYRIGHT 1999 ACS
AN 1986:449054 HCAPLUS
DN 105:49054
TI Total parenteral and **enteral** nutrition composition
IN Park, John Yol
PA American Hospital Supply Corp., USA
SO PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 8600810	A1	19860213	WO 85-US1415	19850724
W: JP				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
CA 1257131	A1	19890711	CA 85-487133	19850719
EP 188602	A1	19860730	EP 85-903930	19850724
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 61502822	T2	19861204	JP 85-503477	19850724
PRAI US 84-635089	19840727			
WO 85-US1415	19850724			

AB A stable **fat** emulsion compn. for parenteral or **enteral** nutrition contains a **fat**, amino acids including lysine and arginine, and **carbohydrates**. The emulsion is stabilized by a combination of coemulsifiers comprising a phosphatide such as egg or soybean phosphatide and a **fatty** acid-amino acid **peptide** wherein the **fatty** acid component is a satd. or unsatd. C16-22 **fatty** acid. Thus, a compn. for **enteral** nutrition was

prepd. contg. 9 L-amino acids, corn **oil**, lecithin, mono- and diglycerides, maltodextrin, sucrose, and di-Na linoleoyl-L-glutamate.

IT **52-90-4D**, N-**fatty** acyl derivs. **56-40-6D**, N-**fatty** acyl derivs. **56-41-7D**, N-**fatty** acyl derivs. **56-45-1D**, N-**fatty** acyl derivs. **56-84-8D**, N-**fatty** acyl derivs. **56-86-0D**, N-**fatty** acyl derivs. **56-87-1D**, N-**fatty** acyl derivs. **60-18-4D**, N-**fatty** acyl derivs. **61-90-5D**, N-**fatty** acyl derivs. **63-68-3D**, N-**fatty** acyl derivs. **63-91-2D**, N-**fatty** acyl derivs. **71-00-1D**, N-**fatty** acyl derivs. **72-18-4D**, N-**fatty** acyl derivs. **72-19-5D**, N-**fatty** acyl derivs. **73-22-3D**, N-**fatty** acyl derivs. **73-32-5D**, N-**fatty** acyl derivs. **74-79-3D**, N-**fatty** acyl derivs. **147-85-3D**, N-**fatty** acyl derivs.
RL: BIOL (Biological study)
(**fat** emulsions contg. phosphatides and, for **enteral** and parenteral nutrition)

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:10:57 ON 19 APR 1999
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 16 APR 99 HIGHEST RN 221295-00-7
DICTIONARY FILE UPDATES: 18 APR 99 HIGHEST RN 221295-00-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 13, 1999

Please note that search-term pricing does apply when conducting SmartSELECT searches.

=> d ide can tot

L69 ANSWER 1 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **7782-49-2** REGISTRY
CN Selenium (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN C.I. 77805
DR 12640-29-8, 12640-30-1, 12641-96-2, 12733-65-2, 11125-23-8, 11133-88-3, 95788-45-7, 50954-17-1, 51882-60-1, 37256-19-2, 37258-85-8, 37276-15-6, 37368-02-8
MF Se
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, APILIT, APILIT2, APIPAT, APIPAT2, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CHEMSAFE, CIN, CSCHEM, CSNB, DETHERM*, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, TOXLINE, TOXLIT, TRCTHERMO*, TULSA, ULIDAT, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Se

41375 REFERENCES IN FILE CA (1967 TO DATE)
1524 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
41410 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:231534

REFERENCE 2: 130:231521

REFERENCE 3: 130:231476

REFERENCE 4: 130:231458

REFERENCE 5: 130:231328

REFERENCE 6: 130:231281

REFERENCE 7: 130:230986

REFERENCE 8: 130:230823

REFERENCE 9: 130:230770

REFERENCE 10: 130:230378

L69 ANSWER 2 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **7235-40-7** REGISTRY
CN .beta.,.beta.-Carotene (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN .beta.-Carotene, all-trans- (8CI)
OTHER NAMES:
CN (all-E)-1,1'-(3,7,12,16-Tetramethyl-1,3,5,7,9,11,13,15,17-octadecanonaene-1,18-diyl)bis[2,6,6-trimethylcyclohexene]
CN .beta.-Carotene
CN all-E-.beta.-Carotene
CN all-trans-.beta.-Carotene
CN Betacarotene
CN C.I. Food Orange 5
CN Cyclohexene, 1,1'-(3,7,12,16-tetramethyl-1,3,5,7,9,11,13,15,17-octadecanonaene-1,18-diyl)bis[2,6,6-trimethyl-, (all-E)-
CN Food Orange 5
CN KPMK
CN Lucarotin
CN Provatenol
CN Rovimix
CN Serlabo
FS STEREOSEARCH
DR 116-32-5, 31797-85-0
MF C40 H56
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, APILIT, APILIT2, APIPAT, APIPAT2, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMLIST, CBNB, CIN, CSCHEM, CSNB, DETHERM*, DDFU, DRUGU, EMBASE, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



7961 REFERENCES IN FILE CA (1967 TO DATE)
84 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7969 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:229858

REFERENCE 2: 130:227729

REFERENCE 3: 130:223445

REFERENCE 4: 130:222515

REFERENCE 5: 130:222509

REFERENCE 6: 130:222426

REFERENCE 7: 130:222310

REFERENCE 8: 130:221015

REFERENCE 9: 130:220585

REFERENCE 10: 130:220448

L69 ANSWER 3 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **541-15-1** REGISTRY
CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (2R)-(9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, (R)-
CN Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, L-(8CI)
OTHER NAMES:

CN (-)-Carnitine
CN (-)-L-Carnitine
CN (R)-Carnitine
CN 1-Propanaminium, 3-carboxy-2-hydroxy-N,N,N-trimethyl-, inner salt, (R)-
CN Carnitine
CN Carnitine, (-)-
CN L-(-)-Carnitine
CN L-Carnitine
CN l-Carnitine
CN Levocarnitine
CN ST 198
CN Vitamin BT
FS STEREOSEARCH
DR 7634-98-2, 101512-81-6, 4209-27-2
MF C7 H15 N O3
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PHAR, PROMT, RTECS*, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



3034 REFERENCES IN FILE CA (1967 TO DATE)
648 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3037 REFERENCES IN FILE CAPLUS (1967 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:227501

REFERENCE 2: 130:222560

REFERENCE 3: 130:221645

REFERENCE 4: 130:220169

REFERENCE 5: 130:213657

REFERENCE 6: 130:207091

REFERENCE 7: 130:205539

REFERENCE 8: 130:204888

REFERENCE 9: 130:200748

REFERENCE 10: 130:194698

L69 ANSWER 4 OF 26 REGISTRY COPYRIGHT 1999 ACS

RN **147-85-3** REGISTRY
CN L-Proline (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Proline, L- (8CI)
OTHER NAMES:
CN (-)-(S)-Proline
CN (-)-2-Pyrrolidinecarboxylic acid
CN (-)-Proline
CN (S)-2-Pyrrolidinecarboxylic acid
CN (S)-Proline
CN 2-Pyrrolidinecarboxylic acid
CN 2-Pyrrolidinecarboxylic acid, (S)-
CN L-(-)-Proline
CN L-.alpha.-Pyrrolidinecarboxylic acid
CN L-Pyrrolidine-2-carboxylic acid
CN Proline
FS STEREOSEARCH
DR 7005-20-1
MF C5 H9 N O2
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



18144 REFERENCES IN FILE CA (1967 TO DATE)
749 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
18152 REFERENCES IN FILE CAPLUS (1967 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:227729

REFERENCE 2: 130:227541

REFERENCE 3: 130:226161

REFERENCE 4: 130:223565

REFERENCE 5: 130:222521

REFERENCE 6: 130:222518

REFERENCE 7: 130:222352

REFERENCE 8: 130:222351

REFERENCE 9: 130:222340

REFERENCE 10: 130:222325

L69 ANSWER 5 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **107-35-7** REGISTRY
CN Ethanesulfonic acid, 2-amino- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Taurine (8CI)
OTHER NAMES:
CN .beta.-Aminoethylsulfonic acid
CN 1-Aminoethane-2-sulfonic acid
CN 2-Aminoethanesulfonic acid
CN 2-Aminoethylsulfonic acid
CN 2-Sulfoethylamine
CN O-Due
CN Taufon
CN Taukard
CN Tauphon
FS 3D CONCORD
DR 91105-79-2
MF C2 H7 N O3 S
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, CSNB, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



8227 REFERENCES IN FILE CA (1967 TO DATE)
428 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8232 REFERENCES IN FILE CAPLUS (1967 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:229090

REFERENCE 2: 130:227542

REFERENCE 3: 130:227535

REFERENCE 4: 130:222988

REFERENCE 5: 130:222560

REFERENCE 6: 130:222523

REFERENCE 7: 130:221661

REFERENCE 8: 130:220685

REFERENCE 9: 130:220626

REFERENCE 10: 130:220593

L69 ANSWER 6 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **74-79-3** REGISTRY
CN L-Arginine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Arginine, L- (8CI)
OTHER NAMES:
CN (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid
CN Arginine
CN L-(+)-Arginine
CN L-.alpha.-Amino-.delta.-guanidinovaleric acid
CN L-Norvaline, 5-[(aminoiminomethyl)amino]-
CN L-Ornithine, N5-(aminoiminomethyl)-
CN Pentanoic acid, 2-amino-5-[(aminoiminomethyl)amino]-, (S)-
FS STEREOSEARCH
DR 7004-12-8, 142-49-4
MF C6 H14 N4 O2
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PHAR, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



24495 REFERENCES IN FILE CA (1967 TO DATE)
701 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
24512 REFERENCES IN FILE CAPLUS (1967 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:227769

REFERENCE 3: 130:227746

REFERENCE 4: 130:227554

REFERENCE 5: 130:222523

REFERENCE 6: 130:222521

REFERENCE 7: 130:222518

REFERENCE 8: 130:222517

REFERENCE 9: 130:222408

REFERENCE 10: 130:222352

L69 ANSWER 7 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **73-32-5** REGISTRY
CN L-Isoleucine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Isoleucine, L- (8CI)
OTHER NAMES:
CN (2S,3S)-.alpha.-Amino-.beta.-methyl-n-valeric acid
CN (2S,3S)-.alpha.-Amino-.beta.-methylvaleric acid
CN (2S,3S)-2-Amino-3-methylpentanoic acid
CN (S)-Isoleucine
CN (S,S)-Isoleucine
CN 2-Amino-3-methylvaleric acid
CN 2S,3S-Isoleucine
CN erythro-L-Isoleucine
CN Isoleucine
CN L-(+)-Isoleucine
CN L-Norvaline, 3-methyl-, erythro-
CN Pentanoic acid, 2-amino-3-methyl-, [S-(R*,R*)]-
CN [S-(R*,R*)]-2-Amino-3-methylpentanoic acid
FS STEREOSEARCH
DR 7004-09-3
MF C6 H13 N O2
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



13393 REFERENCES IN FILE CA (1967 TO DATE)
272 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
13404 REFERENCES IN FILE CAPLUS (1967 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:227541

REFERENCE 3: 130:223163

REFERENCE 4: 130:222717

REFERENCE 5: 130:222523

REFERENCE 6: 130:222521

REFERENCE 7: 130:222518

REFERENCE 8: 130:222517

REFERENCE 9: 130:222352

REFERENCE 10: 130:222351

L69 ANSWER 8 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **73-22-3** REGISTRY
CN L-Tryptophan (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Tryptophan, L- (8CI)
OTHER NAMES:
CN (-)-Tryptophan
CN (S)-.alpha.-Amino-.beta.-indolepropionic acid
CN (S)-.alpha.-Amino-1H-indole-3-propanoic acid
CN (S)-.alpha.-Aminoindole-3-propionic acid
CN (S)-Tryptophan
CN 1H-Indole-3-alanine, (S)-
CN 1H-Indole-3-propanoic acid, .alpha.-amino-, (S)-
CN 2-Amino-3-indolylpropanoic acid
CN 3-Indol-3-ylalanine
CN EH 121
CN L-(-)-Tryptophan
CN l-.alpha.-Aminoindole-3-propionic acid
CN l-.beta.-3-Indolylalanine
CN L-Alanine, 3-(1H-indol-3-yl)-
CN L-Tryptophane
CN Tryptophan
CN Tryptophane
FS STEREOSEARCH
DR 6912-86-3, 80206-30-0
MF C11 H12 N2 O2
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PHAR, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



23534 REFERENCES IN FILE CA (1967 TO DATE)
954 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
23545 REFERENCES IN FILE CAPLUS (1967 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:227541

REFERENCE 3: 130:223543

REFERENCE 4: 130:223471

REFERENCE 5: 130:222518

REFERENCE 6: 130:222517

REFERENCE 7: 130:222408

REFERENCE 8: 130:222351

REFERENCE 9: 130:222340

REFERENCE 10: 130:222303

L69 ANSWER 9 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **72-19-5** REGISTRY
CN L-Threonine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Threonine, L- (8CI)
OTHER NAMES:
CN (S)-Threonine
CN 2-Amino-3-hydroxybutyric acid
CN Butanoic acid, 2-amino-3-hydroxy-, [R-(R*,S*)]-
CN L-(-)-Threonine
CN Threonin
CN Threonine
CN [R-(R*,S*)]-2-Amino-3-hydroxybutanoic acid
AR 7004-04-8
FS STEREOSEARCH
DR 13095-55-1, 36676-50-3
MF C4 H9 N O3
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, APILIT, APILIT2, APIPAT, APIPAT2, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PHAR, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU

(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



15598 REFERENCES IN FILE CA (1967 TO DATE)
379 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
15610 REFERENCES IN FILE CAPLUS (1967 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:231620

REFERENCE 3: 130:222717

REFERENCE 4: 130:222523

REFERENCE 5: 130:222518

REFERENCE 6: 130:222517

REFERENCE 7: 130:222352

REFERENCE 8: 130:222351

REFERENCE 9: 130:222340

REFERENCE 10: 130:220257

L69 ANSWER 10 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **72-18-4** REGISTRY
CN L-Valine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Valine, L- (8CI)
OTHER NAMES:
CN (S)-.alpha.-Amino-.beta.-methylbutyric acid
CN (S)-2-Amino-3-methylbutanoic acid
CN (S)-2-Amino-3-methylbutyric acid
CN (S)-Valine
CN 2-Amino-3-methylbutanoic acid
CN Butanoic acid, 2-amino-3-methyl-, (S)-
CN L-(+)-.alpha.-Aminoisovaleric acid
CN L-.alpha.-Amino-.beta.-methylbutyric acid
CN Valine
FS STEREOSEARCH
DR 7004-03-7, 16872-32-5
MF C5 H11 N O2

CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



17252 REFERENCES IN FILE CA (1967 TO DATE)
551 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
17264 REFERENCES IN FILE CAPLUS (1967 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:227769

REFERENCE 3: 130:227541

REFERENCE 4: 130:222523

REFERENCE 5: 130:222518

REFERENCE 6: 130:222517

REFERENCE 7: 130:222408

REFERENCE 8: 130:222352

REFERENCE 9: 130:222351

REFERENCE 10: 130:222340

L69 ANSWER 11 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **71-00-1** REGISTRY
CN L-Histidine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Histidine, L- (8CI)
OTHER NAMES:
CN (S)-.alpha.-Amino-1H-imidazole-4-propanoic acid
CN (S)-4-(2-Amino-2-carboxyethyl)imidazole
CN (S)-Histidine
CN 1H-Imidazole-4-alanine, (S)-
CN 1H-Imidazole-4-propanoic acid, .alpha.-amino-, (S)-
CN Glyoxaline-5-alanine
CN Histidine

CN L-(-)-Histidine
CN L-Alanine, 3-(1H-imidazol-4-yl)-
FS STEREOSEARCH
DR 7006-35-1, 150-35-6, 54166-13-1, 155304-24-8, 35479-49-3, 35558-59-9, 45955-20-2
MF C6 H9 N3 O2
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, ULIDAT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



21627 REFERENCES IN FILE CA (1967 TO DATE)
1036 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
21641 REFERENCES IN FILE CAPLUS (1967 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:227769

REFERENCE 3: 130:223543

REFERENCE 4: 130:222523

REFERENCE 5: 130:222521

REFERENCE 6: 130:222518

REFERENCE 7: 130:222517

REFERENCE 8: 130:222352

REFERENCE 9: 130:222351

REFERENCE 10: 130:222340

L69 ANSWER 12 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **70-47-3** REGISTRY
CN L-Asparagine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Asparagine, L- (8CI)
OTHER NAMES:
CN (-)-Asparagine
CN (S)-2,4-Diamino-4-oxobutanoic acid

CN (S)-Asparagine
CN .alpha.-Aminosuccinamic acid
CN Agedoite
CN Altheine
CN Asn
CN Asparagine
CN Asparagine acid
CN Asparamide
CN Aspartamic acid
CN Aspartic acid .beta.-amide
CN Aspartic acid amide
CN Butanoic acid, 2,4-diamino-4-oxo-, (S)-
CN Crystal VI
CN L-.beta.-Asparagine
CN L-2,4-Diamino-4-oxobutanoic acid
CN l-Asparagine
CN L-Aspartamine
FS STEREOSEARCH
DR 7006-34-0, 328-41-6, 32640-57-6
MF C4 H8 N2 O3
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, SPECINFO, TOXLINE, TOXLIT, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



9078 REFERENCES IN FILE CA (1967 TO DATE)
319 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
9080 REFERENCES IN FILE CAPLUS (1967 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:222717

REFERENCE 3: 130:222523

REFERENCE 4: 130:220399

REFERENCE 5: 130:220257

REFERENCE 6: 130:220169

REFERENCE 7: 130:219836

REFERENCE 8: 130:219802

REFERENCE 9: 130:219776

REFERENCE 10: 130:219638

L69 ANSWER 13 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **63-91-2** REGISTRY
CN L-Phenylalanine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Alanine, phenyl-, L- (7CI, 8CI)
OTHER NAMES:
CN (-)-.beta.-Phenylalanine
CN (-)-Phenylalanine
CN (S)-(-)-Phenylalanine
CN (S)-.alpha.-Amino-.beta.-phenylpropionic acid
CN (S)-.alpha.-Aminobenzenepropanoic acid
CN (S)-.alpha.-Aminohydrocinnamic acid
CN (S)-2-Amino-3-phenylpropanoic acid
CN (S)-2-Amino-3-phenylpropionic acid
CN (S)-Phenylalanine
CN .beta.-Phenyl-.alpha.-alanine
CN .beta.-Phenyl-L-alanine
CN .beta.-Phenylalanine
CN 3-Phenyl-L-alanine
CN 3-Phenylalanine
CN Antibiotic FN 1636
CN Benzenepropanoic acid, .alpha.-amino-, (S)-
CN L-(-)-Phenylalanine
CN L-Alanine, 3-phenyl-
CN Phenyl-.alpha.-alanine
CN Phenylalanine
FS STEREOSEARCH
DR 10549-09-4, 3617-44-5, 67675-33-6, 5297-02-9
MF C9 H11 N O2
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, CSNB, DETHERM*, DDFU, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, ULIDAT, USAN, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



22144 REFERENCES IN FILE CA (1967 TO DATE)
767 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
22157 REFERENCES IN FILE CAPLUS (1967 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231643

REFERENCE 2: 130:231628

REFERENCE 3: 130:227541

REFERENCE 4: 130:223543

REFERENCE 5: 130:222798

REFERENCE 6: 130:222523

REFERENCE 7: 130:222518

REFERENCE 8: 130:222517

REFERENCE 9: 130:222366

REFERENCE 10: 130:222352

L69 ANSWER 14 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **63-68-3** REGISTRY
CN L-Methionine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Methionine, L- (8CI)
OTHER NAMES:
CN (S)-2-Amino-4-(methylthio)butanoic acid
CN .alpha.-Amino-.gamma.-methylmercaptobutyric acid
CN .gamma.-Methylthio-.alpha.-aminobutyric acid
CN 2-Amino-4-(methylthio)butyric acid
CN Butanoic acid, 2-amino-4-(methylthio)-, (S)-
CN Cymethion
CN L-(-)-Methionine
CN L-.alpha.-Amino-.gamma.-methylthiobutyric acid
CN L-Homocysteine, S-methyl-
CN l-Methionine
CN Methionine
CN S-Methionine
FS STEREOSEARCH
DR 7005-18-7, 24425-78-3
MF C5 H11 N O2 S
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, CSNB, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



22304 REFERENCES IN FILE CA (1967 TO DATE)
566 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
22318 REFERENCES IN FILE CAPLUS (1967 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:227541

REFERENCE 2: 130:222560

REFERENCE 3: 130:222524

REFERENCE 4: 130:222523

REFERENCE 5: 130:222518

REFERENCE 6: 130:222517

REFERENCE 7: 130:222416

REFERENCE 8: 130:222402

REFERENCE 9: 130:222366

REFERENCE 10: 130:222352

L69 ANSWER 15 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **61-90-5** REGISTRY
CN L-Leucine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Leucine, L- (8CI)
OTHER NAMES:
CN (S)-(+)-Leucine
CN (S)-2-Amino-4-methylpentanoic acid
CN (S)-2-Amino-4-methylvaleric acid
CN (S)-Leucine
CN L-(+)-Leucine
CN L-.alpha.-Aminoisocaproic acid
CN L-Norvaline, 4-methyl-
CN Leu
CN Leucine
CN Pentanoic acid, 2-amino-4-methyl-, (S)-
FS STEREOSEARCH
DR 7005-03-0
MF C6 H13 N O2
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



20745 REFERENCES IN FILE CA (1967 TO DATE)
499 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
20759 REFERENCES IN FILE CAPLUS (1967 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:227769

REFERENCE 3: 130:227541

REFERENCE 4: 130:223557

REFERENCE 5: 130:222523

REFERENCE 6: 130:222521

REFERENCE 7: 130:222518

REFERENCE 8: 130:222517

REFERENCE 9: 130:222366

REFERENCE 10: 130:222352

L69 ANSWER 16 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **60-18-4** REGISTRY
CN L-Tyrosine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Tyrosine, L- (8CI)
OTHER NAMES:
CN (-)-.alpha.-Amino-p-hydroxyhydrocinnamic acid
CN (S)-.alpha.-Amino-4-hydroxybenzenepropanoic acid
CN (S)-Tyrosine
CN Benzenepropanoic acid, .alpha.-amino-4-hydroxy-, (S)-
CN L-p-Tyrosine
CN L-Phenylalanine, 4-hydroxy-
CN p-Tyrosine
CN Propanoic acid, 2-amino-3-(4-hydroxyphenyl)-, (S)-
CN Tyrosine
FS STEREOSEARCH
DR 140-43-2, 55520-40-6, 1991-85-1, 46209-14-7
MF C9 H11 N O3
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PHAR, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



25496 REFERENCES IN FILE CA (1967 TO DATE)
756 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
25513 REFERENCES IN FILE CAPLUS (1967 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:231398

REFERENCE 3: 130:223543

REFERENCE 4: 130:222523

REFERENCE 5: 130:222518

REFERENCE 6: 130:222517

REFERENCE 7: 130:222352

REFERENCE 8: 130:222351

REFERENCE 9: 130:222340

REFERENCE 10: 130:221974

L69 ANSWER 17 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **56-87-1** REGISTRY
CN L-Lysine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Lysine, L- (8CI)
OTHER NAMES:
CN (+)-S-Lysine
CN (S)-.alpha.,.epsilon.-Diaminocaproic acid
CN (S)-2,6-Diaminohexanoic acid
CN (S)-Lysine
CN .alpha.-Lysine
CN 2,6-Diaminohexanoic acid
CN Aminutrin
CN Hexanoic acid, 2,6-diamino-, (S)-
CN L-(+)-Lysine
CN L-Norleucine, 6-amino-
CN Lysine
CN Lysine acid
FS STEREOSEARCH
DR 6899-06-5, 48050-57-3
MF C6 H14 N2 O2

CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



28970 REFERENCES IN FILE CA (1967 TO DATE)
1067 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
28983 REFERENCES IN FILE CAPLUS (1967 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:227769

REFERENCE 3: 130:227746

REFERENCE 4: 130:222523

REFERENCE 5: 130:222521

REFERENCE 6: 130:222518

REFERENCE 7: 130:222517

REFERENCE 8: 130:222402

REFERENCE 9: 130:222352

REFERENCE 10: 130:222351

L69 ANSWER 18 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **56-86-0** REGISTRY
CN L-Glutamic acid (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glutamic acid, L- (7CI, 8CI)
OTHER NAMES:
CN (2S)-2-Aminopentanedioic acid
CN (S)-(+)-Glutamic acid
CN (S)-2-Aminopentanedioic acid
CN (S)-Glutamic acid
CN .alpha.-Aminoglutaric acid
CN .alpha.-Glutamic acid
CN 1-Aminopropane-1,3-dicarboxylic acid
CN 2-Aminoglutaric acid
CN 2-Aminopentanedioic acid

CN Aciglut
CN Glusate
CN Glutacid
CN Glutamic acid
CN Glutamicol
CN Glutamidex
CN Glutaminic acid
CN Glutaminol
CN Glutaton
CN L-(+)-Glutamic acid
CN L-.alpha.-Aminoglutaric acid
CN l-Glutaminic acid
CN L-Glutaminic acid
CN Pentanedioic acid, 2-amino-, (S)-
FS STEREOSEARCH
DR 6899-05-4, 10549-13-0, 138-16-9
MF C5 H9 N O4
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, APILIT, APILIT2, APIPAT, APIPAT2, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, CSNB, DETHERM*, DDFU, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, ULIDAT, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



39812 REFERENCES IN FILE CA (1967 TO DATE)
1323 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
39842 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:231628

REFERENCE 2: 130:228400

REFERENCE 3: 130:227769

REFERENCE 4: 130:227703

REFERENCE 5: 130:227529

REFERENCE 6: 130:227528

REFERENCE 7: 130:227527

REFERENCE 8: 130:227515

REFERENCE 9: 130:227514

REFERENCE 10: 130:227057

L69 ANSWER 19 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **56-85-9** REGISTRY
CN L-Glutamine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glutamine, L- (8CI)
OTHER NAMES:
CN (S)-2,5-Diamino-5-oxopentanoic acid
CN .gamma.-Glutamine
CN 2-Aminoglutaramic acid
CN Cebrogen
CN Glumin
CN Glutamic acid 5-amide
CN Glutamic acid amide
CN Glutamine
CN L-(+)-Glutamine
CN L-2-Aminoglutaramidic acid
CN L-Glutamic acid .gamma.-amide
CN Levoglutamide
CN Pentanoic acid, 2,5-diamino-5-oxo-, (S)-
CN Stimulina
FS STEREOSEARCH
DR 32640-56-5
MF C5 H10 N2 O3
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PROMT, RTECS*, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



14848 REFERENCES IN FILE CA (1967 TO DATE)
262 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
14854 REFERENCES IN FILE CAPLUS (1967 TO DATE)
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:222523

REFERENCE 2: 130:221646

REFERENCE 3: 130:221354

REFERENCE 4: 130:221256

REFERENCE 5: 130:220950

REFERENCE 6: 130:220944

REFERENCE 7: 130:220626

REFERENCE 8: 130:220593

REFERENCE 9: 130:220494

REFERENCE 10: 130:220257

L69 ANSWER 20 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **56-84-8** REGISTRY
CN L-Aspartic acid (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Aspartic acid, L- (8CI)
OTHER NAMES:
CN (+)-Aspartic acid
CN (S)-Aminobutanedioic acid
CN (S)-Aspartic acid
CN Asparagic acid
CN Asparaginic acid
CN Aspartic acid
CN Butanedioic acid, amino-, (S)-
CN H-Asp-OH
CN L-(+)-Aspartic acid
CN L-Aminosuccinic acid
CN L-Asparagic acid
CN L-Asparaginic acid
FS STEREOSEARCH
DR 6899-03-2, 181119-33-5
MF C4 H7 N O4
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, ULIDAT, USAN, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



24401 REFERENCES IN FILE CA (1967 TO DATE)
840 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
24420 REFERENCES IN FILE CAPLUS (1967 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:229934

REFERENCE 2: 130:228400

REFERENCE 3: 130:227769

REFERENCE 4: 130:227529

REFERENCE 5: 130:227528

REFERENCE 6: 130:227527

REFERENCE 7: 130:223602

REFERENCE 8: 130:223575

REFERENCE 9: 130:222523

REFERENCE 10: 130:222518

L69 ANSWER 21 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **56-45-1** REGISTRY
CN L-Serine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Serine, L- (8CI)
OTHER NAMES:
CN (-)-Serine
CN (S)-.alpha.-Amino-.beta.-hydroxypropionic acid
CN (S)-2-Amino-3-hydroxypropanoic acid
CN (S)-Serine
CN .beta.-Hydroxy-L-alanine
CN L-(-)-Serine
CN L-3-Hydroxy-2-aminopropionic acid
CN L-Alanine, 3-hydroxy-
CN Propanoic acid, 2-amino-3-hydroxy-, (S)-
CN Serine
FS STEREOSEARCH
DR 6898-95-9
MF C3 H7 N O3
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



20056 REFERENCES IN FILE CA (1967 TO DATE)
589 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
20068 REFERENCES IN FILE CAPLUS (1967 TO DATE)

8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:227775

REFERENCE 3: 130:222523

REFERENCE 4: 130:222521

REFERENCE 5: 130:222518

REFERENCE 6: 130:222517

REFERENCE 7: 130:222352

REFERENCE 8: 130:222351

REFERENCE 9: 130:222340

REFERENCE 10: 130:221256

L69 ANSWER 22 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **56-41-7** REGISTRY
CN L-Alanine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Alanine, L- (7CI, 8CI)
OTHER NAMES:
CN (S)-(+)-Alanine
CN (S)-2-Aminopropanoic acid
CN (S)-Alanine
CN .alpha.-Alanine
CN .alpha.-Aminopropionic acid
CN Alanine
CN L-(+)-Alanine
CN L-.alpha.-Alanine
CN L-.alpha.-Aminopropionic acid
CN L-2-Aminopropanoic acid
CN L-2-Aminopropionic acid
CN Propanoic acid, 2-amino-, (S)-
FS STEREOSEARCH
DR 6898-94-8, 170805-71-7, 115967-49-2
MF C3 H7 N O2
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DETHERM*, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



25726 REFERENCES IN FILE CA (1967 TO DATE)
952 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
25743 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231643

REFERENCE 2: 130:231628

REFERENCE 3: 130:229940

REFERENCE 4: 130:227774

REFERENCE 5: 130:227769

REFERENCE 6: 130:227541

REFERENCE 7: 130:223739

REFERENCE 8: 130:223586

REFERENCE 9: 130:222717

REFERENCE 10: 130:222523

L69 ANSWER 23 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **56-40-6** REGISTRY
CN Glycine (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Aminoacetic acid
CN Acetic acid, amino-
CN Aciport
CN Aminoacetic acid
CN Aminoethanoic acid
CN Glicoamin
CN Glycocoll
CN Glycolixir
CN Glycosthene
CN Padil
FS 3D CONCORD
DR 57678-19-0, 87867-94-5, 52955-63-2
MF C2 H5 N O2
CI COM
LC STN Files: AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, CSNB, DETHERM*, DDFU, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



33052 REFERENCES IN FILE CA (1967 TO DATE)
2251 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
33074 REFERENCES IN FILE CAPLUS (1967 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231628

REFERENCE 2: 130:229940

REFERENCE 3: 130:228400

REFERENCE 4: 130:227771

REFERENCE 5: 130:227769

REFERENCE 6: 130:227746

REFERENCE 7: 130:227729

REFERENCE 8: 130:227554

REFERENCE 9: 130:227529

REFERENCE 10: 130:227528

L69 ANSWER 24 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **52-90-4** REGISTRY
CN L-Cysteine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cysteine, L- (8CI)
OTHER NAMES:
CN (R)-2-Amino-3-mercaptopropanoic acid
CN (R)-Cysteine
CN .beta.-Mercaptoalanine
CN 2-Amino-3-mercaptopropionic acid
CN Cystein
CN Cysteine
CN Half-cystine
CN L-(+)-Cysteine
CN L-Alanine, 3-mercapto-
CN NSC-8746
CN Propanoic acid, 2-amino-3-mercapto-, (R)-
CN Thioserine
FS STEREOSEARCH
DR 4371-52-2
MF C3 H7 N O2 S
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, CSNB, DETHERM*, DDFU, DRUGU,

EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, ULIDAT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



21743 REFERENCES IN FILE CA (1967 TO DATE)
1088 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
21759 REFERENCES IN FILE CAPLUS (1967 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231533

REFERENCE 2: 130:227325

REFERENCE 3: 130:223553

REFERENCE 4: 130:222640

REFERENCE 5: 130:222523

REFERENCE 6: 130:222446

REFERENCE 7: 130:222171

REFERENCE 8: 130:220815

REFERENCE 9: 130:220307

REFERENCE 10: 130:220234

L69 ANSWER 25 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **50-99-7** REGISTRY
CN D-Glucose (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN (+)-Glucose
CN Anhydrous dextrose
CN Cartose
CN Cerelose
CN Cerelose 2001
CN Corn sugar
CN D(+)-Glucose
CN Dextropur
CN Dextrose
CN Dextrosol
CN Glucolin
CN Glucose
CN Glucosteril
CN Grape sugar
CN Staleydex 111

CN Staleydex 333
CN Sugar, grape
CN Tabfine 097(HS)
CN Vadex
FS STEREOSEARCH
DR 8012-24-6, 8030-23-7, 162222-91-5, 165659-51-8, 50933-92-1, 80206-31-1
MF C6 H12 O6
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CHEMSAFE, CIN, CSCHEM, CSNB, DETHERM*, DDFU, DIPPR*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, ULIDAT, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



99308 REFERENCES IN FILE CA (1967 TO DATE)
1665 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
99363 REFERENCES IN FILE CAPLUS (1967 TO DATE)
14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231599

REFERENCE 2: 130:231584

REFERENCE 3: 130:228258

REFERENCE 4: 130:227769

REFERENCE 5: 130:227738

REFERENCE 6: 130:227719

REFERENCE 7: 130:227703

REFERENCE 8: 130:227641

REFERENCE 9: 130:227640

REFERENCE 10: 130:227636

L69 ANSWER 26 OF 26 REGISTRY COPYRIGHT 1999 ACS
RN **50-81-7** REGISTRY
CN L-Ascorbic acid (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN (+)-Ascorbic acid

CN 3-keto-L-Gulofuranolactone
CN 3-Oxo-L-gulofuranolactone
CN Adenex
CN Allercorb
CN Antiscorbic vitamin
CN Antiscorbutic vitamin
CN Ascoltin
CN Ascorbajen
CN Ascorbic acid
CN Ascorbutina
CN Ascorin
CN Ascorteal
CN Ascorvit
CN C-Quin
CN C-Vimin
CN Cantan
CN Cantaxin
CN Catavin C
CN Ce-Mi-Lin
CN Ce-Vi-Sol
CN Cebicure
CN Cebion
CN Cebione
CN Cecon
CN Cegiolan
CN Ceglion
CN Celaskon
CN Celin
CN Cemagyl
CN Cenetone
CN Cereon
CN Cergona
CN Cescorbat
CN Cetamid
CN Cetemican
CN Cevalin
CN Cevatine
CN Cevex
CN Cevimin
CN Cevital
CN Cevitamic acid
CN Cevitamin
CN Cevitan
CN Cevitex
CN Chewcee
CN Ciamin
CN Cipca
CN Citrovit
CN Colascor
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
FS STEREOSEARCH
DR 56533-05-2, 57304-74-2, 57606-40-3, 56172-55-5, 129940-97-2, 14536-17-5, 50976-75-5, 89924-69-6, 30208-61-8
MF C6 H8 O6
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, APILIT, APILIT2, APIPAT, APIPAT2, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN,

CSCHEM, CSNB, DETHERM*, DDFU, DIPPR*, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PHAR, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, TULSA, ULIDAT, USAN, USPATFULL, VETU, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



36945 REFERENCES IN FILE CA (1967 TO DATE)
883 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
36979 REFERENCES IN FILE CAPLUS (1967 TO DATE)
12 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 130:231570

REFERENCE 2: 130:231498

REFERENCE 3: 130:230895

REFERENCE 4: 130:229081

REFERENCE 5: 130:227789

REFERENCE 6: 130:227742

REFERENCE 7: 130:227712

REFERENCE 8: 130:227625

REFERENCE 9: 130:222554

REFERENCE 10: 130:222439

=> fil frosti

FILE 'FROSTI' ENTERED AT 14:42:51 ON 19 APR 1999
COPYRIGHT (C) 1999 Leatherhead Food Research Association

FILE LAST UPDATED: 15 APR 1999 <19990415/UP>

=> d his l113-

(FILE 'FROSTI' ENTERED AT 14:35:53 ON 19 APR 1999)
E MARK D/AU
L113 7 S E4
E TWYMAN D/AU

```
L114          3 S E3
                E MICHALSKI T/AU
L115          9 S L113,L114
L116      59930 S (PROTEIN OR PEPTIDE OR POLYPEPTIDE OR WHEY OR NITROGEN SOURCE
L117       6139 S L116 AND (CARBOHYDRATE OR POLYSACCHARIDE OR DEXTROSE OR GLUCO
L118       3497 S L117 AND (LIPID OR TRIGLYCERIDE OR GLYCERIDE OR GLYCERIDIC OR
L119         21 S L118 AND ENTERAL?
L120          6 S L115 NOT L119
L121          5 S L120 NOT FISH/TI
L122         20 S L118 AND FORTIFIED FOODS/CT
L123         40 S L118 AND DIETETIC FOODS/CT
L124          6 S L118 AND MEDICAL FOODS/CT
L125          1 S L118 AND HOSPITAL FOODS/CT
L126          1 S L118 AND PAEDIATRIC FOODS/CT
L127          1 S L118 AND PAEDIATRIC MEDICAL FOODS/CT
L128         20 S L118 AND MEDICAL TREATMENT/CT
L129          3 S L122,L123 AND L124-L128
L130          7 S L121,L129
L131         12 S L124-L127,L130
L132          0 S L128 AND L124-L127
L133          2 S L128 AND L122,L123
L134         12 S L131,L133
L135         21 S L118 AND ENTERAL?
L136         31 S L134,L135

     FILE 'FROSTI' ENTERED AT 14:42:51 ON 19 APR 1999

=> d all tot l136


L136  ANSWER 1 OF 31  FROSTI  COPYRIGHT 1999 LFRA
AN    486010   FROSTI
TI    Product and method for providing glutamine.
IN    Trimbo S.L.; Melin C.; Boza J.
PA    Societe des Produits Nestle SA
SO    PCT Patent Application
PI    WO 9854985  A1
AI    19980506
PRAI  United States  19970602
DT    Patent
LA    English
SL    English
AB    Glutamine supplementation has been shown to be valuable to patients
      during periods of illness and health stress.  Preterm babies and athletes
      after exercise have less than optimal levels of glutamine.  A nutritional
      product and a method for delivering glutamine to a patient are disclosed.
      The product has a protein source, which includes a cereal
    protein (oat, sorghum or millet protein).  The product
      also includes a carbohydrate source and a lipid
      source.  It may be in the form of an enteral formulation; it
      may also be designed for administration to animals.  (See also WO
      98/54986.)
CT    ANIMAL DIETARY SUPPLEMENTS; ATHLETES; DIETARY SUPPLEMENTS; DIETETIC
      FOODS; ENTERAL FEEDING; GLUTAMINE SUPPLEMENTS; INFANTS; PATENT;
      PATIENTS; PCT PATENT; PRETERM INFANTS; SPORTSMEN
DED   11 Feb 1999

L136  ANSWER 2 OF 31  FROSTI  COPYRIGHT 1999 LFRA
AN    475012   FROSTI
```

TI Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract.
IN Arnaud-Battandier F.; Jaussan V.; Grasset E.
PA Societe des Produits Nestle SA
SO European Patent Application
PI EP 852913 A1
AI 19971224
PRAI European Patent Office 19970114
DT Patent
LA English
SL English
AB This invention relates to an **enteral**, nutritional composition for use in the treatment of gastrointestinal conditions such as Crohn's disease. It does not involve steroid treatment and so avoids its undesirable side effects. The composition contains casein that is rich in TGF-beta2, a **lipid** source, and a **carbohydrate** source. The composition can be in the form of a soluble powder, a liquid concentrate or a ready-to-use formulation. It can be administered by nasogastric tube. Alternatively, the formulation can form a supplement to normal food sources, and patients can drink it. A number of examples are described in detail.
CT CASEIN; CROHNS DISEASE; DIETARY SUPPLEMENTS; DIETETIC FOODS; DISEASES; EUROPEAN PATENT; INTESTINAL DISEASES; MILK **PROTEIN**; MILK **PROTEINS**; PATENT; **PROTEIN**; **PROTEIN** SUPPLEMENTS; **PROTEINS**
DED 4 Sep 1998

L136 ANSWER 3 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 466288 FROSTI
TI Nutritional formula for phenylketonuria patients.
IN Masson G.; Monti J.C.; Ballevre O.
PA Societe des Produits Nestle SA
SO PCT Patent Application
PI WO 9808402 A1
AI 19970825
PRAI European Patent Office 19960830
DT Patent
LA English
SL English
AB The nutritional formula contains as a **protein** source a mixture of caseino-glyco-macropeptide together with complementary amino acids, apart from phenylalanine, which provide a balanced amino acid profile. The formula can be used alone as a **protein** supplement, or as a complete diet when it is mixed with a **carbohydrate** and a **fat** source, and vitamins and minerals.
CT DIET; **MEDICAL FOODS**; NUTRITIONAL SUPPLEMENTS; PCT PATENT; PHENYLALANINE FREE DIETS; PHENYLKETONURIA
DED 30 Apr 1998

L136 ANSWER 4 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 455128 FROSTI
TI Method and formula for the prevention of diarrhea.
IN Halpin-Dohnalek M.I.; Hilty M.D.; Bynum D.G.
PA Abbott Laboratories
SO PCT Patent Application
PI WO 9735596 A1
AI 19970325
PRAI United States 19960325
DT Patent

LA English
SL English
AB The invention relates to compositions for the prevention of infectious diarrhoea or diarrhoea caused by antibiotic therapy. The composition includes a powder comprising viable cultures of the probiotic bacteria Lactobacillus reuteri, Lactobacillus acidophilus and Bifidobacterium infantis. The powder is mixed with a liquid and consumed on a daily basis. Pills or capsules containing the lyophilized cultures are also disclosed, as well as powdered nutritional formulations containing the probiotic cultures mixed with **protein**, **fat** and **carbohydrates**. The powdered nutritional formula may also be in the form of a complete infant formula. The probiotic system described has been shown by clinical studies to be effective in the prevention of diarrhoea. Methods for manufacturing the compositions and formula are disclosed.
CT BACTERIA; BIFIDOBACTERIUM INFANTIS; DIARRHOEA; HEALTH FOODS; INFANT FORMULAS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS REUTERI; **MEDICAL FOODS**; PCT PATENT; PREVENTION; PROBIOTIC CULTURES; PROBIOTICS; TREATMENT
DED 18 Nov 1997

L136 ANSWER 5 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 443956 FROSTI
TI Soluble amylose cornstarch is more digestible than soluble amylopectin potato starch in rats.
AU Zhou X.; Kaplan M.L.
SO Journal of Nutrition, 1997, (July), 127 (7), 1349-1356 (30 ref.)
DT Journal
LA English
SL English
AB Because of their high digestibility and water solubility, low-molecular-weight **carbohydrates** such as **glucose** are widely used in liquid nutritional supplements and **enteral** formulations. However, they have an undesirable degree of osmolarity and high glycaemic indices. High-molecular-weight **carbohydrates** have been suggested as alternatives. Male rats were fed either commercial cornstarch, **dextrose**, modified soluble potato (70-75% amylopectin) starch, or modified soluble amylomaize-7 (70% amylose) starch for 4 weeks. Total food consumption was higher in the groups fed modified potato starch and amylomaize-7 starch, but there were no differences in body weight among the four groups. The digestibility of the modified potato starch was lower than that of the two control **carbohydrates** and the modified amylomaize-7 starch-fed groups. The modified potato starch and amylomaize-7 starch groups had significantly higher body water as a proportion of body weight than the controls, and higher liver weights. Modified potato-starch-fed rats had a lower energy efficiency than the other groups. In food-deprived rats, serum free **fatty** acid concentrations in the modified potato-starch-fed group were higher and serum **protein** concentrations were lower than in the other groups. The insulin to glucagon ratios were lower in the two modified-starch-fed groups than in the two control groups. The results suggest that amylomaize-7 starch may be useful in liquid nutritional supplements because of its high digestibility and low resultant insulin levels.
SH NUTRITION
CT AMYLOPECTIN; AMYLOSE; DIETARY SUPPLEMENTS; DIGESTIBILITY; **GLUCOSE** ; STARCH
DED 10 Sep 1997

L136 ANSWER 6 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 440043 FROSTI
TI Nutritional support of paediatric patients.
IN Trimbo S.L.; Kruseman J.; Kruzel C.; **Mark D.A.**; Reddy S.
PA Societe des Produits Nestle SA
SO PCT Patent Application
PI WO 9716079 A1
AI 19961015
PRAI United States 19951027
DT Patent
LA English
SL English
AB The invention aims to produce a nutritional formula designed for paediatric patients in general, as well as paediatric patients recovering from trauma, post-surgical and moderate traumatic burns, and injuries. The composition includes sources of **protein**, **carbohydrate** and **lipid**. The **protein** source, which is in the form of casein and **whey**, provides 10-14% of the total calories. The **lipid** source consists of medium- and long-chain **triglycerides**.
CT **FORTIFIED FOODS; HOSPITAL FOODS; MEDICAL FOODS; PAEDIATRIC FOODS; PAEDIATRIC MEDICAL FOODS** ; PCT PATENT
DED 11 Jul 1997

L136 ANSWER 7 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 436977 FROSTI
TI Therapeutic food composition and method to diminish blood sugar fluctuations.
IN Kaufman F.
PA Children's Hospital of Los Angeles
SO European Patent Application
PI EP 765126
WO 9631129 19961010
AI 19950825
PRAI United States 19950407
DT Patent
LA English
SL English
AB The patent describes a medicinal food for the treatment of diabetes, which is designed to reduce blood sugar level fluctuations and prevent hypoglycaemia. The food includes a slowly absorbed/digested complex **carbohydrate**, such as cornstarch; a more rapidly absorbed complex **carbohydrate**; **protein**; and **fat**. It is substantially free from simple sugars. The food is preferably administered as an evening or pre-bedtime snack, or it can be administered during the day to patients on insulin therapy or those whose activities make them prone to hypoglycaemia.
CT ANTIHYPOGLYCAEMIC FOODS; DIABETIC FOODS; EUROPEAN PATENT; **MEDICAL FOODS**
DED 10 Jun 1997

L136 ANSWER 8 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 434730 FROSTI
TI Diabetic nutritional product having controlled absorption of **carbohydrate**.
IN Wilbert G.J.; Keating K.R.; Greene H.L.; Lee Y.-H.
PA Bristol-Myers Squibb Co.
SO European Patent Application

PI EP 768043 A2
DS AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
AI 19961015
PRAI United States 19951016
DT Patent
LA English
SL English
AB A nutritional composition for use by diabetics is described. It contains a **carbohydrate** component that can be absorbed in a controlled manner. **Carbohydrate** is supplied in three forms: **glucose** or sucrose that is rapidly absorbed; fructose or specified cooked starches that are absorbed moderately rapidly; and raw corn starch to provide a slowly absorbed fraction. These provide a sustained release of **carbohydrate** without leading to excessive increases in blood **glucose** levels. The **fat** content is moderate to low, and **protein hydrolysate** may also be included. The formulation may be prepared as a nutritionally complete formulation, for **enteral** feeding, as a beverage, as a pudding, or as a confectionery bar or granola bar. Artificial flavourings may be added as required.
CT **CARBOHYDRATES**; DIABETIC FOODS; EUROPEAN PATENT
DED 2 May 1997

L136 ANSWER 9 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 434612 FROSTI
TI Composition for nutrition.
IN Windenband A.; Pausch G.; Karsten S.
PA B. Braun Melsungen AG
SO European Patent Application
PI EP 756827 A1
DS BE; DE; ES; FR; GB; IT; NL
AI 19960730
PRAI Germany, Federal Republic of 19950803
DT Patent
LA German
SL German
AB The invention relates in particular to improved liquid nutritional compositions for patients with a weakened immune function or tumours, and contains **protein** and/or **protein hydrolysates**, **carbohydrates**, **fat**, fibre and water. The **fat** content comprises only 20-30 energy% and has specified **fatty** acid ratios. The composition includes glutamine and gamma-linolenic acid. The invention provides a fully balanced special food for sole or supplementary **enteral** and/or oral feeding. Where desirable, the **fat** content can be increased.
CT EUROPEAN PATENT; HIGH; HIGH NUTRITIONAL VALUE; IMPROVED; LIQUID FOODS; NUTRITIONAL VALUE
DED 1 May 1997

L136 ANSWER 10 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 434561 FROSTI
TI Nutritional composition.
IN Alexander J.; Gray D.; Mark D.A.; Schmelkin N.; Twyman D.
PA Clintec Nutrition Co.
SO European Patent Application
PI EP 764405 A2
DS AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
AI 19960920
PRAI United States 19950920

DT Patent
LA English
SL English
AB An **enteral** nutritional formulation is disclosed that meets the nutrient requirements of patients in intensive care who may have decreased capacity for nutrient absorption. The composition contains **protein** and **carbohydrate** sources and a **lipid** source incorporating medium-chain **triglycerides**, and omega-3 and omega-6 **fatty** acids. **Protein hydrolysate** accounts for 80-85% of the composition, with 15-20% of free amino acids. The **hydrolysate** is produced using pancreatic enzymes rather than microbial enzymes. Cysteine is supplied in a proportion sufficient to replenish intracellular glutathione levels in the patient being treated. The composition is supplied in a ready-to-use formulation, reducing risks of bacterial contamination during mixing.
CT **ENTERAL**; EUROPEAN PATENT; **HYDROLYSATES**; MEDICAL TREATMENT; MEDICINAL FOODS; NUTRITIONAL VALUE; **PROTEIN HYDROLYSATES**; **PROTEINS**
DED 1 May 1997

L136 ANSWER 11 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 432462 FROSTI
TI **Enteral** and parenteral nutrition.
AU Brooks S.; Kearns P.
SO Present knowledge in nutrition. (7th edition) Published by: ILSI, Washington DC, 1996, 530-539 (82 ref.)
Ziegler E.E.
ISBN: 0-944398-72-3
DT Book Article
LA English
AB Therapeutic uses of **enteral** and parenteral nutrition for intervention in acute and chronic disease states are examined. A model of nutritional intervention emphasises the need to screen many people to identify individuals at risk of complications from poor nutritional status. With sufficient evidence from randomised, controlled trials, clinical nutrition is used to improve nutritional status while limiting harm to the patient. **Enteral** and parenteral nutrition are discussed in terms of historical perspective, clinical nutritional assessment, nutritional needs, and route of nutritional support. Indications for **enteral** nutrition, classification of **enteral** formulae, **glucose** polymers as **carbohydrate** source, partially hydrolysed **protein** or elemental diets, and targeted formulations are described. Indications for parenteral nutrition, **fat**, and minerals are considered. Nutrition in specific diseases, designer nutrients, and ethics are discussed.
SH NUTRITION
CT APPLICATIONS; DEVELOPMENT; DISEASES; **ENTERAL**; EVALUATION; IMPROVEMENT; NUTRIENTS; NUTRITION; NUTRITIONAL STATUS; PARENTERAL; RECIPES; RESEARCH
DED 12 Feb 1997

L136 ANSWER 12 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 425043 FROSTI
TI Nutritional compositions in various forms.
IN Grote R.; James M.; Lin P.; **Mark D.A.**; Schmelkin N.
PA Clintec Nutrition Co.
SO European Patent Application
PI EP 745333 A1

DS AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
AI 19960530
PRAI United States 19950601
DT Patent
LA English
SL English
AB Nutritional compositions are described for administration to patients in long-term care, such as the elderly. Protein provides 14-25% of the energy content, and 40-75% is derived from carbohydrate. The preparations can be given in solid, semi-solid or liquid form. A range of forms and flavours may be used to provide variety in the diet. These are intended to be nutritionally interchangeable. Other conditions for which the compositions are suitable include AIDS, protein/calorie malnutrition or risk of this, deficiency of a specific nutrient, and malabsorption.
CT DIETETIC FOODS; ELDERLY PEOPLE; EUROPEAN PATENT; INSTITUTIONS; MEDICAL TREATMENT; NUTRITIONAL VALUE; PATIENTS
DED 6 Jan 1997

L136 ANSWER 13 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 423816 FROSTI
TI **Enteral** formula with ribo-nucleotides.
IN Masor M.L.; Leach J.L.; Molitor B.E.; Benson J.D.; Baxter J.H.
PA Abbott Laboratories
SO European Patent Application
PI EP 739207
WO 9518618 19950713
DS AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
AI 19950105
PRAI United States 19940110
DT Patent
LA English
SL English
AB The invention relates to an improved **enteral** nutritional formula, in particular an infant formula, that is claimed to be superior to human milk in enhancing the immune system and treating diarrhoea. The formula contains nucleotide equivalents (RNA, mono-, di- and triphosphate nucleotides, nucleosides and adjuncts such as activated sugars) at a level of at least 10 mg/100 Kcal of formula. The formula comprises **carbohydrates**, **lipids**, **proteins**, vitamins and minerals, and four nucleotide equivalents in specific proportions. (See also EP 0 739 169 (WO 95/18547)).
CT BABIES; EUROPEAN PATENT; FUNCTIONAL FOODS; IMMUNITY; IMPROVEMENT; INCREASE; INSTANT FORMULA; MILK
DED 6 Dec 1996

L136 ANSWER 14 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 406424 FROSTI
TI Low-**protein** nutritive food material composition.
IN Shimizu T.; Matsui K.; Ito M.; Shimamura U.
PA Nippon Oil & Fats Co. Ltd
SO Japanese Patent Application
PI JP 07123919 A 19950516
AI 19931102
NTE 19950516
DT Patent
LA Japanese
SL English
AB The patent describes a nutritional composition suitable for patients with

nutritional disorders requiring a low-**protein**, low-mineral diet. The composition contains 30-80 wt% of a medium-chain, saturated **fatty** acid **triglyceride**, preferably containing caprylic acid and capric acid; 10-50 wt% of hydrolysed starch, preferably low-saccharified starch with a **dextrose** equivalent of 2-30; 5-20 wt% of dietary fibre, preferably a combination of insoluble fibre such as cellulose or lignin, with soluble fibre such as hemicellulose; and up to 8 wt% of an organic acid monoglyceride.

CT DIET; JAPANESE PATENT; LOW MINERAL; LOW **PROTEIN**; **MEDICAL FOODS**; NUTRITIONAL COMPOSITION

DED 18 Apr 1996

L136 ANSWER 15 OF 31 FROSTI COPYRIGHT 1999 LFRA

AN 402447 FROSTI

TI **Enteral** composition for diabetic patients.

IN Alexander J.; Chang S.-Y.; Dobbie R.; Grasset E.; Kamarei A.R.; Laughlin P.; Lin P.; Melin C.; Reddy S.

PA Clintec Nutrition Co.

SO European Patent Application

PI EP 691079 A2

DS AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE

AI 19950706

PRAI United States 19940706

DT Patent

LA English

SL English

AB A nutritional supplement is designed for providing nutrition to diabetic patients without substantially increasing blood **glucose** levels. The formulation includes a **protein** source, a **carbohydrate** source and a **fat** source that includes medium-chain **triglycerides** and has an n-6:n-3 ratio of no more than 10. Both soluble and insoluble dietary fibres are also included. High-amylose starch can be included in the **carbohydrate** fraction as it is digested at a slower rate than other starches and leads to a reduction in the rate at which **glucose** enters the blood stream.

CT DIABETES; EUROPEAN PATENT; **MEDICAL FOODS**; NUTRITIONAL SUPPLEMENTS

DED 22 Feb 1996

L136 ANSWER 16 OF 31 FROSTI COPYRIGHT 1999 LFRA

AN 378435 FROSTI

TI **Enteral** nutrient.

IN Sotozono S.

PA Otsuka Pharmaceut Co. Ltd

SO Japanese Patent Application

PI JP 06181718 A 19940705

AI 19921221

NTE 19940705

DT Patent

LA Japanese

SL English

AB This patent describes a nutritional composition, suitable for enteric administration in hospitals. It contains a purified **protein** obtained from Phaseolus radiatus L. The composition is claimed to have no side-effects, can be used in cases of lactose intolerance, has a high nutritional value, and is easily digested. It consists of **protein**, including the putified P. radiatus **protein**, **carbohydrate** such as **glucose**, and **fat** or

oil, in specified amounts.
CT HIGH; HIGH NUTRITIONAL VALUE; HIGH **PROTEIN**; HIGH QUANTITY; HOSPITAL FOOD; LACTOSE INTOLERANCE; NUTRITIONAL VALUE; PATENTS; PHASEOLUS; **PROTEINS**; RADIATUS
DED 18 Jul 1995

L136 ANSWER 17 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 377121 FROSTI
TI Nutritional compositions for management of nitrogen metabolism.
IN Madsen D.C.; Mark D.A.
PA Clintec Nutrition Co.
SO European Patent Application
PI EP 656178 A2
DS AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE
AI 19941128
PRAI United States 19931203
DT Patent
LA English
SL English
AB A nutritional product is described that is designed for patients with liver and kidney conditions that impair the ability to detoxify ammonia produced from certain amino acids in the diet. The composition contains **protein**, **lipid** and **carbohydrates**, and has an amino acid profile giving less than 20% of ammoniagenic amino acids. It is particularly low in ornithine and citrulline. The product can be administered **enterally** or parenterally. Excess nitric oxide production is also avoided by this formulation.
CT AMINO ACIDS; AMMONIA; CITRULLINE; DISEASES; **ENTERAL**; KIDNEY DISEASES; KIDNEYS; LIVER; LIVER DISEASES; MEDICAL TREATMENT; MEDICINAL FOODS; METABOLIC DISEASES; METABOLISM; ORNITHINE; PARENTERAL; PATENTS
DED 6 Jul 1995

L136 ANSWER 18 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 377114 FROSTI
TI Compositions and their use for retarding the aging process.
IN Kamerei A.R.; Goldberg D.I.; **Mark D.A.**; Pace G.
PA Free Radical Sciences Inc.
SO European Patent Application
PI EP 655245 A2
DS CH; DE; ES; FR; GB; IT; LI; SE
AI 19941031
PRAI United States 19931101
DT Patent
LA English
SL English
AB This patent describes methods and compositions claimed to retard the ageing process in mammals. The compositions are designed to maintain intracellular levels of glutathione at such a level as to prevent oxidative and free radical damage to cells. The composition includes at least one stimulator of intracellular glutathione synthesis chosen from L-2-oxothiazolidine-4-carboxylate; esters of L-2-oxothiazolidine-4-carboxylate; glutathione esters; and proteins rich in cysteine. The composition can be administered in a number of ways including through the diet.
CT GLUTATHIONE; HEALTH FOODS; HUMAN AGEING; PATENTS; QUANTITY; RATE; REDUCTION; SLOWING; STIMULATION
DED 6 Jul 1995

L136 ANSWER 19 OF 31 FROSTI COPYRIGHT 1999 LFRA

AN 361129 FROSTI
TI Composition for **enteral** nutrition.
IN Schulz S.; Kessler B.; Roosen U.; Riedel A.
PA Fresenius AG.
SO European Patent Application
PI EP 611568 A1
DS AT; CH; DE; DK; ES; FR; GB; IT; LI; SE
AI 19940204
PRAI Germany, Federal Republic of 19930213
DT Patent
LA German
SL German
AB Compositions for **enteral** nutrition, particularly of patients with tumours, are disclosed. The compositions are formulated in line with the special metabolic conditions of tumour patients (who suffer from weight loss) by combining a high **fat** content with special **fat** component. The latter is characterised by its **fatty** acid pattern and its ratio of omega-3 **fatty** acids to omega-6 **fatty** acids. In relation to the whole composition, the **fat** content may provide 40-65% of energy, the **protein** content 12-25% and the **carbohydrate** content 20-45%.
CT CACHEXIA; CANCER; **FATS**; HIGH; HIGH **FAT**; HIGH **FAT** FOOD; HIGH QUANTITY; MEDICINAL FOODS; PATENTS; PATIENTS; TUMOURS
DED 5 Jan 1995

L136 ANSWER 20 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 361094 FROSTI
TI Composition and method for reducing the risk of hypotension.
IN **Mark D.A.**; Pace G.
PA Clintec Nutrition Co.
SO European Patent Application
PI EP 612522 A1
DS AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
AI 19931103
PRAI United States 19921105
DT Patent
LA English
AB An enteral nutritional composition is disclosed for patients at risk of hypotension owing to disease states such as sepsis and Crohn's disease. The product contains a significantly reduced arginine content, but provides an adequate quantity of dietary protein, etc. The arginine content is reduced in order to reduce the formation of nitric oxide in the patient.
CT ARGININE; CROHNS DISEASE; FEEDING; MEDICINAL FOODS; PATENTS; PATIENTS; REDUCTION
DED 5 Jan 1995

L136 ANSWER 21 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 352035 FROSTI
TI Benefits and complications of parenteral nutritional support.
AU Nordenstrom J.; Thorne A.
SO European Journal of Clinical Nutrition, 1994, 48 (8), 531-537 (33 ref.)
DT Journal
LA English
AB It is generally believed that parenteral nutrition given to patients before or after major surgery can reduce complications after surgery. However, some studies have failed to show that total parenteral nutrition (TPN) is definitely of benefit to patients undergoing operations. This

paper reviews 3 recent studies concerning the use of TPN before and after surgery. The benefits and risks of TPN in surgical patients are also outlined. Several factors concerning TPN are discussed. These include the amount of energy supplied, the ratio of **glucose:fat** of non-**protein** energy, nitrogen intake, the timing of TPN initiation and administration techniques. The results from the studies indicate that TPN is of benefit to patients with pre-existing malnutrition who cannot obtain enough nutrients by the **enteral** route.

SH NUTRITION
CT ENERGY; HEALTH; INTAKE; NITROGEN; NUTRITION; PARENTERAL; PATIENTS; SAFETY; SURGERY
DED 23 Sep 1994

L136 ANSWER 22 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 337347 FROSTI
TI Low caloric density **enteral** formulation designed to reduce diarrhoea in tube-fed patients.
IN Mark D.A.
PA Clintec Nutrition Co.
SO European Patent Application
PI EP 570791 A2
DS AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
AI 19930510
PRAI United States 19920521
DT Patent
LA English
SL English
AB An **enteral** product is described for providing nutritional requirements to tube-fed patients. The proposed sterile product reduces the risk of diarrhoea and does not need diluting. Existing **enteral** products need to be diluted and do not provide essential minerals and vitamins. The proposed **enteral** nutritional product consists of one or more of insoluble soy **polysaccharide**, hydrolysed plant gums, insoluble pectin, carob pod and extract of carob pod. The product also has 35-50% of the total calories as **fat** and 25% of the total calories as **protein**.
CT CAROB; CAROB GUM; DIARRHOEA; FEEDING; FORTIFIED FOODS; GUMS; HIGH; HIGH NUTRITIONAL VALUE; INHIBITION; NUTRIENTS; NUTRITIONAL VALUE; PATENTS; **POLYSACCHARIDES**; TUBES
DED 10 Mar 1994

L136 ANSWER 23 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 336952 FROSTI
TI Improved high protein liquid nutrition for patients with elevated wound healing requirements.
IN Trimbo S.L.; **Twyman D.**
PA Clintec Nutrition Co.
SO European Patent Application
PI EP 564804 A1
DS AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; NL; PT; SE
AI 19930227
PRAI United States 19920410
DT Patent
LA English
SL English
AB A high-protein liquid nutrition formula for patients with elevated wound healing requirements is described, as is a method for treating such patients. The formula contains a protein source, a fat source, a

carbohydrate source, a zinc source, a vitamin C source, a selenium source, a vitamin A source (including beta-carotene) and a thiamin source.
CT FORTIFIED FOODS; HEALING; HIGH; HIGH PROTEIN; HIGH QUANTITY; IMPROVEMENT; LIQUIDS; PATENTS; PROTEINS
DED 1 Mar 1994

L136 ANSWER 24 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 321521 FROSTI
TI Nutrient content of foods: Special dietary formulas, commercial and hospital.
AU Pennington J.A.T.;Church H.N.; Bowes A.D.P.
SO Bowes and Church's food values of portions commonly used. (16th ed.) Published by: J.B. Lippincott Company., Philadelphia, 1993, 277-284 (0 ref.)
Pennington J.A.T.;Church H.N.; Bowes A.D.P.
ISBN: 0-397-55087-1
NTE REFERENCE ONLY
DT Book Article
LA English
AB This section provides a guide to the nutrient content of special dietary preparations including **enteral** formulas. The following nutrient contents are tabulated for a given serving size: kcal, water, **protein**, **carbohydrate**, fibre, **fat**, saturated **fatty** acids, monounsaturated **fatty** acids, polyunsaturated **fatty** acids, cholesterol, vitamin A (as retinol and IU), vitamin C, vitamin B-2, vitamin B-6, folic acid, vitamin B-1, niacin, vitamin B-12, pantothenic acid, sodium, calcium, magnesium, zinc, manganese, potassium, phosphorus, iron, and copper. The majority of the branded products originate in the US.
SH CONVENIENCE FOODS
CT COMPOSITION; CONVENIENCE FOODS; FORTIFYING AGENTS; HOSPITALS; MEDICINAL FOODS; NUTRIENTS; NUTRITIONAL VALUE; PORTIONS; QUANTITY; TABLE; TYPE
DED 22 Jul 1993

L136 ANSWER 25 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 262381 FROSTI
TI **Enteral** diet for patients with pulmonary disease.
IN Bracco U.; Rowe B.W.; Trimbo S.L.
PA NB International Technologies.
SO European Patent Application
PI EP 395865 A2
PRAI United States 19890505
DT Patent
LA English
AB The diet provides caloric requirements for the patients from **lipids** rather than **carbohydrate** sources. It also provides a calorie source which is readily available to the respiratory muscle, and a source of high quality **protein** to support and maintain muscle structure and function: 18% of the calories are derived from a high quality **protein** source; 20-50% of the calories are from a slowly metabolizable **carbohydrate** source derived from maltodextrin or other partially hydrolysed **polysaccharides**; 40-55% of the calories are from a mixture of **lipids** comprising medium and long chain tryglycerides.
CT **CARBOHYDRATES**; DIETETIC FOODS; **ENTERAL** FOODS; **LIPIDS**; MALTODEXTRIN; MALTODEXTRINS; PATENTS; PRODUCTION; **PROTEINS**
DED 13 Nov 1990

L136 ANSWER 26 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 246938 FROSTI
TI **Enteral** and parenteral nutrition.
AU Ament M.E.
SO Present knowledge in nutrition (6th edition) Published by: International Life Sciences Institute Nutrition Foundation, Washington DC, 1990, 444-50 (32 ref.)
edited by Brown M.L.
DT Book Article
LA English
AB The assessment of nutritional status and the treatment of malnutrition by parental and **enteral** feeding are discussed.
CT **CARBOHYDRATES**; DEFICIENCY; DETERMINATION; DIET; ENERGY; **ENTERAL**; **ENTERAL** FOODS; **FATS**; FEEDING; IDENTIFICATION; LIQUID FOODS; MEDICAL TREATMENT; NUTRIENTS; NUTRITIONAL STATUS; PARENTERAL; PARENTERAL FOOD; **PROTEINS**; REQUIREMENTS; VITAMINS; WATER
DED 7 Feb 1991

L136 ANSWER 27 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 234358 FROSTI
TI Inflammatory bowel disease; Nutritional implications and treatment.
AU Silk D.B.A.; Payne-James J.
SO Proceedings of the Nutrition Society, 1989, 48 (3), 355-61 (52 ref.)
NTE Paper presented at a symposium 'The Interaction between Nutrition and Inflammation', held at the 455th Meeting of the Nutrition Society, University of Southampton, 1988.
DT Journal
LA English
CT ABSORPTION; BODY WEIGHT LOSS; **CARBOHYDRATES**; COLITIS; CROHNS DISEASE; DEFICIENCY; DIET; DISEASES; **ENTERAL**; **FATS**; FEEDING; HEALTH; MAGNESIUM; METABOLISM; MINERALS; NUTRITIONAL STATUS; PARENTERAL; **PROTEINS**; ULCERATIVE; VITAMINS; WEIGHT LOSS; ZINC
DED 23 Jul 1990

L136 ANSWER 28 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 234054 FROSTI
TI Manual of dietetic practice.
AU Thomas B.; British Dietetic Association.
SO Oxford: Blackwell Scientific Publications, 638pp. REFERENCE ONLY., 1988
ISBN: 0-632-01481-4
DT Book
AB This manual gives a basic guide to dietetic principles and practice. A reference section on foods and nutrients complements a detailed description of therapeutic dietetics. The nutritional needs of population sub-groups and special dietetic practices are also covered.
CT ADDITIVES; ADOLESCENTS; ADVICE; ALLERGENS; ALLERGIES; AMINO ACIDS; ASIAN; ASIAN FOODS; ATHLETES; BABIES; BASIC GUIDE; BENZOATES; BLOOD; BONE DISEASES; BRAIN DISEASES; CAFFEINE; **CARBOHYDRATES**; CARIES; CHILDREN; CHINESE; CHINESE FOODS; DEFICIENCY; DESIGN; DETERMINATION; DIABETES; DIABETIC FOODS; DIET; **DIETETIC FOODS**; DISEASES; DRUGS; DUODENUM; EGGS; ENERGY; **ENTERAL**; EVALUATION; FAD; FAECES; **FATS**; FEMALES; FIBRE; **GLUCOSE** TOLERANCE FACTOR; GLUTAMATES; GLUTEN; HEALTH; HEALTH FOODS; HEART DISEASE; HOMOCYSTINURIA; HUMANS; HYPERLIPIDAEMIA; HYPERLIPOPROTEINAEMIA; INFANT FOODS; INSTITUTIONS; INTAKE; INTERACTIONS; INTERVENTION; INTESTINAL DISEASES; INTOLERANCE; JEWISH; KIDNEY DISEASES; KOSHER FOODS; LABELLING;

LACTOSE; LARYNX; LEGISLATION; LIQUID FOODS; LIQUIDS; LIVER DISEASES; MANAGEMENT; **MEDICAL TREATMENT**; MENTAL DISEASES; METABOLISM; MILK; MINERALS; MONOAMINE; MOUTH; NUTRIENTS; NUTRITION; NUTRITIONAL STATUS; NUTRITIONAL VALUE; OBESITY; OESOPHAGUS; OXALATES; PANCREAS; PARENTERAL; PHARYNX; PHENYLKETONURIA; PORTIONS; POVERTY; PRADER WILLI SYNDROME; PREGNANT WOMEN; PREVENTION; **PROTEINS**; PURINES; RASTAFARIAN; RECOMMENDED; REDUCTION; REQUIREMENTS; RESEARCH; SALICYLATES; SEMI; SENIOR CITIZENS; SIZE; SKIN; SOLID FOODS; STOMACH DISEASES; SWEETENERS; THEOBROMINE; THEOPHYLLINE; THYROID; TRACE ELEMENTS; URINE; VEGAN DIETS; VEGETARIAN DIETS; VIETNAMESE; VIETNAMESE FOOD; VITAMINS; WHEAT; WOMEN; YEASTS
DED 5 Jul 1990

L136 ANSWER 29 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 226935 FROSTI
TI A step-wise approach to calculating modular feedings.
AU Brylinsky C.M.; Bastion C.H.
SO Journal of the American Dietetic Association, 1989, 89 (10), 1489-91 (17 ref.)
DT Journal
LA English
AB This article discusses a method for calculating modular feedings using conventional commercial formulas and common modular **enteral** products.
CT **CARBOHYDRATES**; DEVELOPMENT; ENERGY; **ENTERAL**; **ENTERAL** FOODS; **FATS**; FEEDING; **PROTEINS**
DED 27 Apr 1990

L136 ANSWER 30 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 220342 FROSTI
TI Tube-fed nourishment and a process for the production thereof.
IN Strinning O.; Sjoberg L.B.; Bruner P.-O.; Gebele J.
PA Semper AB
SO European Patent Application
PI EP 350469
DT Patent
LA English
AB A tube-fed nourishment is described, which is of the whole-diet variety and which contains **fats**, **proteins**, **carbohydrates**, vitamins and minerals but is characterised in that it also contains an admixture of fibres from root vegetables. The fibres are soluble and unsoluble and are provided in the same fibre product.
CT 900125; DIET; **ENTERAL** FOODS; FEEDING; FIBRE; HOSPITALS; PATENTS; TUBES
DED 17 Jan 1990

L136 ANSWER 31 OF 31 FROSTI COPYRIGHT 1999 LFRA
AN 61068 FROSTI
TI Fortified milk.
AU Mettler A.E.
SO Journal of the Society of Dairy Technology, 1980, 33 (4), 150-8 (38 ref.)
DT Journal
LA English
SL English
AB The nutritive value of liquid milk and its contribution to the recommended daily intake of nutrients (including **protein**, **fat**, **carbohydrate**, vitamins and inorganic elements) for various groups of people are discussed. Fortified milks are described with reference to the general categories of fortified milks commercially

or technically available, the nutritive value and properties of low-**fat** milk, semi-skimmed and skimmed milks, the development and nutrient contents of fortified milks for dietary purposes i.e. baby foods, slimming foods, complete foods or food supplements and tube feeds, the use of milk and fortified milk products in the treatment of disease or dietary deficiency e.g. heart trouble, lactose tolerance, milk **protein** allergy, and vitamin or mineral deficiency, and filled milk.

CT APPLICATIONS; **CARBOHYDRATES**; DIET; **DIETETIC FOODS**; **FATS**; FILLED; **FORTIFIED FOODS**; FORTIFIED MILK; INFANT FORMULAS; INTAKE; LOW CALORIE FOODS; **MEDICAL TREATMENT**; MEDICINAL FOODS; MILK; NUTRITIONAL VALUE; **PROTEINS**; QUANTITY; SKIMMED MILK; TRACE ELEMENTS; VITAMINS

DED 29 Apr 1981